Involvement	O
of	O
Stat3	B-protein
in	O
interleukin-6	B-protein
-induced	O
IgM	B-protein
production	O
in	O
a	O
human	B-cell_line
B-cell	I-cell_line
line	I-cell_line
.	O

Interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
is	O
an	O
important	O
B-cell	B-protein
growth	I-protein
and	I-protein
differentiation	I-protein
factor	I-protein
.	O

IL-6	B-protein
treatment	O
of	O
the	O
human	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
SKW6.4	B-cell_line
,	O
leads	O
to	O
increased	O
IgM	B-protein
production	O
.	O

We	O
have	O
previously	O
shown	O
that	O
IL-6	B-protein
induces	O
activation	O
of	O
JAK1	B-protein
and	O
JAK2	B-protein
in	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

A	O
chimeric	O
IL-6	B-protein
receptor	I-protein
,	O
comprised	O
of	O
the	O
intracellular	B-protein
tail	I-protein
of	O
the	O
IL-6	B-protein
receptor	I-protein
subunit	I-protein
gp130	B-protein
fused	O
to	O
the	O
extracellular	B-protein
domain	I-protein
of	O
the	O
epidermal	B-protein
growth	I-protein
factor	I-protein
(	I-protein
EGF	I-protein
)	I-protein
receptor	I-protein
,	O
was	O
stably	O
transfected	O
into	O
SKW6.4	B-cell_line
cells	I-cell_line
.	O

EGF	O
treatment	O
induced	O
IgM	B-protein
production	O
in	O
cells	O
transfected	O
with	O
an	O
intact	O
gp130	B-protein
cytoplasmic	I-protein
tail	I-protein
,	O
but	O
not	O
in	O
untransfected	B-cell_line
cells	I-cell_line
or	O
cells	O
transfected	O
with	O
a	O
cytoplasmic	B-protein
tail	I-protein
lacking	O
all	O
four	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
binding	I-protein
sites	I-protein
.	O

Moreover	O
,	O
EGF	O
treatment	O
induced	O
Stat3	B-protein
phosphorylation	O
in	O
cells	O
transfected	O
with	O
the	O
intact	O
chimeric	B-protein
EGF-gp130	I-protein
receptor	I-protein
along	O
with	O
induction	O
of	O
DNA-mobility	O
shift	O
of	O
a	O
classical	B-DNA
interferon-gamma-activated	I-DNA
site	I-DNA
.	O

To	O
define	O
further	O
the	O
relation	O
between	O
Stat3	B-protein
activation	O
and	O
enhanced	O
IgM	B-protein
production	O
,	O
we	O
determined	O
the	O
effect	O
of	O
chimeric	O
gp130	O
on	O
the	O
transcriptional	O
activation	O
of	O
a	O
genetic	O
element	O
linked	O
to	O
immunoglobulin	B-protein
production	O
,	O
namely	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
(	O
IgH-enhancer	B-DNA
)	O
.	O

Parental	O
as	O
well	O
as	O
transfected	O
SKW6.4	B-cell_line
cells	I-cell_line
were	O
transiently	O
transfected	O
with	O
an	O
IgH-enhancer-luciferase	B-DNA
construct	I-DNA
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
IgH-luciferase	B-DNA
construct	I-DNA
was	O
induced	O
upon	O
ligation	O
of	O
the	O
full-length	B-protein
chimeric	I-protein
receptor	I-protein
but	O
not	O
by	O
truncated	B-protein
gp130	I-protein
receptors	I-protein
.	O

Moreover	O
,	O
the	O
gp130	B-protein
-induced	O
activity	O
of	O
this	O
reporter	B-DNA
gene	I-DNA
was	O
abrogated	O
by	O
Stat3EE	B-protein
,	O
a	O
mutant	O
Stat3	B-protein
incapable	O
of	O
binding	O
DNA	O
.	O

These	O
results	O
indicate	O
that	O
IL-6	B-protein
-induced	O
B-cell	O
differentiation	O
,	O
as	O
measured	O
by	O
IgM	B-protein
production	O
,	O
may	O
be	O
controlled	O
by	O
Stat3	B-protein
proteins	I-protein
.	O

Immunology	NULL
1997	NULL
90	NULL
350-357	NULL
Involvement	NULL
of	NULL
Stat3	NULL
in	NULL
interleukin-6-induced	NULL
Ig	NULL
M	NULL
production	NULL
in	NULL
a	NULL
human	NULL
B-cell	NULL
line	NULL
M.	NULL
FARIS	NULL
,	NULL
*	NULL
N.	NULL
KOKOT	NULL
,	NULL
*	NULL
N.	NULL
STAHL	NULL
t	NULL
&	NULL
A.	NULL
E.	NULL
NEL*	NULL
*Division	NULL
of	NULL
Clinical	NULL
Immunology	NULL
and	NULL
Allergy	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
UCLA	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
CA	NULL
,	NULL
and	NULL
{	NULL
Regeneron	NULL
Pharmaceuticals	NULL
,	NULL
Inc.	NULL
,	NULL
Tarrytown	NULL
,	NULL
NY	NULL
,	NULL
USA	NULL
SUMMARY	NULL
Interleukin-6	NULL
(	NULL
IL-6	NULL
)	NULL
is	NULL
an	NULL
important	NULL
B-cell	NULL
growth	NULL
and	NULL
differentiation	NULL
factor	NULL
.	NULL

IL-6	NULL
treatment	NULL
of	NULL
the	NULL
human	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
,	NULL
SKW6.4	NULL
,	NULL
leads	NULL
to	NULL
increased	NULL
IgM	NULL
production	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
IL-6	NULL
induces	NULL
activation	NULL
of	NULL
JAK1	NULL
and	NULL
JAK2	NULL
in	NULL
human	NULL
B	NULL
cell	NULL
lines	NULL
.	NULL

A	NULL
chimeric	NULL
IL-6	NULL
receptor	NULL
,	NULL
comprised	NULL
of	NULL
the	NULL
intracellular	NULL
tail	NULL
of	NULL
the	NULL
IL-6	NULL
receptor	NULL
subunit	NULL
gp130	NULL
fused	NULL
to	NULL
the	NULL
extracellular	NULL
domain	NULL
of	NULL
the	NULL
epidermal	NULL
growth	NULL
factor	NULL
(	NULL
EGF	NULL
)	NULL
receptor	NULL
,	NULL
was	NULL
stably	NULL
transfected	NULL
into	NULL
SKW6.4	NULL
cells	NULL
.	NULL

EGF	NULL
treatment	NULL
induced	NULL
IgM	NULL
production	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
an	NULL
intact	NULL
gp130	NULL
cytoplasmic	NULL
tail	NULL
,	NULL
but	NULL
not	NULL
in	NULL
untransfected	NULL
cells	NULL
or	NULL
cells	NULL
transfected	NULL
with	NULL
a	NULL
cytoplasmic	NULL
tail	NULL
lacking	NULL
all	NULL
four	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
(	NULL
Stat	NULL
)	NULL
binding	NULL
sites	NULL
.	NULL

Moreover	NULL
,	NULL
EGF	NULL
treatment	NULL
induced	NULL
Stat3	NULL
phosphorylation	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
intact	NULL
chimeric	NULL
EGF-gp130	NULL
receptor	NULL
along	NULL
with	NULL
induction	NULL
of	NULL
DNA-mobility	NULL
shift	NULL
of	NULL
a	NULL
classical	NULL
interferon-y-activated	NULL
site	NULL
.	NULL

To	NULL
define	NULL
further	NULL
the	NULL
relation	NULL
between	NULL
Stat3	NULL
activation	NULL
and	NULL
enhanced	NULL
IgM	NULL
production	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
effect	NULL
of	NULL
chimeric	NULL
gp130	NULL
on	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
a	NULL
genetic	NULL
element	NULL
linked	NULL
to	NULL
immunoglobulin	NULL
production	NULL
,	NULL
namely	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer	NULL
(	NULL
IgH-enhancer	NULL
)	NULL
.	NULL

Parental	NULL
as	NULL
well	NULL
as	NULL
transfected	NULL
SK	NULL
W6.4	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
an	NULL
IgH-enhancer-luciferase	NULL
construct	NULL
.	NULL

The	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IgH-luciferase	NULL
construct	NULL
was	NULL
induced	NULL
upon	NULL
ligation	NULL
of	NULL
the	NULL
full-length	NULL
chimeric	NULL
receptor	NULL
but	NULL
not	NULL
by	NULL
truncated	NULL
gp130	NULL
receptors	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
gp130-induced	NULL
activity	NULL
of	NULL
this	NULL
reporter	NULL
gene	NULL
was	NULL
abrogated	NULL
by	NULL
Stat3EE	NULL
,	NULL
a	NULL
mutant	NULL
Stat3	NULL
incapable	NULL
of	NULL
binding	NULL
DNA	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
IL-6-induced	NULL
B-cell	NULL
differentiation	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
IgM	NULL
production	NULL
,	NULL
may	NULL
be	NULL
controlled	NULL
by	NULL
Stat3	NULL
proteins	NULL
.	NULL

INTRODUCTION	NULL
Interleukin-6	NULL
(	NULL
IL-6	NULL
)	NULL
is	NULL
a	NULL
pleiotropic	NULL
cytokine	NULL
that	NULL
regulates	NULL
acute	NULL
phase	NULL
reactions	NULL
,	NULL
haematopoiesis	NULL
and	NULL
host	NULL
defences	NULL
during	NULL
infection	NULL
and	NULL
inflammation	NULL
.	NULL
``	NULL

IL-6	NULL
exhibits	NULL
multiple	NULL
effects	NULL
on	NULL
the	NULL
immune	NULL
system	NULL
,	NULL
including	NULL
B-lymphocyte	NULL
differentiation	NULL
and	NULL
proliferation	NULL
.	NULL

**	NULL
``	NULL
We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
IL-6	NULL
affects	NULL
two	NULL
human	NULL
B-cell	NULL
lines	NULL
,	NULL
AFIO	NULL
and	NULL
SKW6.4	NULL
,	NULL
differen-tially.©	NULL
While	NULL
IL-6	NULL
induces	NULL
enhanced	NULL
proliferation	NULL
of	NULL
AFIO	NULL
cells	NULL
,	NULL
the	NULL
predominant	NULL
response	NULL
to	NULL
IL-6	NULL
treatment	NULL
in	NULL
SKW6.4	NULL
cells	NULL
is	NULL
enhanced	NULL
IgM	NULL
secretion	NULL
.	NULL
``	NULL

These	NULL
cell	NULL
lines	NULL
provide	NULL
us	NULL
with	NULL
models	NULL
for	NULL
investigating	NULL
the	NULL
IL-6-induced	NULL
signalling	NULL
pathways	NULL
associated	NULL
with	NULL
B-cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
engagement	NULL
of	NULL
the	NULL
IL-6	NULL
receptor	NULL
Received	NULL
3	NULL
September	NULL
1996	NULL
;	NULL
revised	NULL
20	NULL
November	NULL
1996	NULL
;	NULL
accepted	NULL
20	NULL
November	NULL
1996	NULL
.	NULL

Abbreviations	NULL
:	NULL
EGF	NULL
,	NULL
epidermal	NULL
growth	NULL
factor	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
GAS	NULL
,	NULL
interferon-y	NULL
activated	NULL
site	NULL
;	NULL
hSIE	NULL
,	NULL
sis-inducible	NULL
element	NULL
;	NULL
IgH	NULL
,	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
;	NULL
IL-6R	NULL
,	NULL
interleukin-6	NULL
receptor	NULL
;	NULL
JAK	NULL
,	NULL
Janus	NULL
Kinase	NULL
;	NULL
PTK	NULL
,	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
;	NULL
Stat	NULL
,	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
.	NULL

Correspondence	NULL
:	NULL
Dr	NULL
A.	NULL
Nel	NULL
,	NULL
UCLA	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
CIA	NULL
,	NULL
52-175	NULL
CHS	NULL
,	NULL
10833	NULL
Le	NULL
Conte	NULL
Ave	NULL
,	NULL
Los	NULL
Angeles	NULL
,	NULL
CA	NULL
90024	NULL
,	NULL
USA	NULL
.	NULL

(	NULL
IL-6R	NULL
)	NULL
activates	NULL
the	NULL
Janus	NULL
kinase	NULL
(	NULL
JAK	NULL
)	NULL
/signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
(	NULL
Stat	NULL
)	NULL
pathway®	NULL
but	NULL
do	NULL
not	NULL
understand	NULL
how	NULL
this	NULL
pathway	NULL
relates	NULL
to	NULL
B-cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

Specifically	NULL
,	NULL
very	NULL
little	NULL
is	NULL
known	NULL
about	NULL
B-cell-specific	NULL
genes	NULL
which	NULL
are	NULL
targeted	NULL
by	NULL
Stat	NULL
proteins	NULL
.	NULL
``	NULL

''	NULL
``	NULL
Recently	NULL
,	NULL
we	NULL
have	NULL
described	NULL
a	NULL
chimeric	NULL
IL-6R	NULL
which	NULL
consists	NULL
of	NULL
the	NULL
extracellular	NULL
domain	NULL
of	NULL
the	NULL
epidermal	NULL
growth	NULL
factor	NULL
(	NULL
EGF	NULL
)	NULL
receptor	NULL
joined	NULL
to	NULL
the	NULL
intracellular	NULL
domain	NULL
of	NULL
the	NULL
signalling	NULL
subunit	NULL
of	NULL
the	NULL
IL-6R	NULL
,	NULL
namely	NULL
gp130	NULL
.	NULL
``	NULL

'	NULL
Transfection	NULL
of	NULL
COS-1	NULL
cells	NULL
with	NULL
these	NULL
chimeric	NULL
receptors	NULL
followed	NULL
by	NULL
EGF	NULL
treatment	NULL
,	NULL
induced	NULL
the	NULL
activation	NULL
of	NULL
a	NULL
JAK/Stat	NULL
pathway	NULL
along	NULL
with	NULL
increased	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
intracellular	NULL
gp130	NULL
domain	NULL
.	NULL
``	NULL

The	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
gp130	NULL
,	NULL
contains	NULL
several	NULL
regions	NULL
deemed	NULL
essential	NULL
for	NULL
signalling	NULL
through	NULL
the	NULL
IL-6R	NULL
,	NULL
including	NULL
boxes	NULL
1	NULL
and	NULL
2	NULL
known	NULL
to	NULL
bind	NULL
JAK	NULL
kinases	NULL
.	NULL

``	NULL
,	NULL
In	NULL
addition	NULL
,	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
gp130	NULL
carries	NULL
four	NULL
tyrosine-based	NULL
motifs	NULL
,	NULL
with	NULL
the	NULL
consensus	NULL
sequence	NULL
YXXQ	NULL
,	NULL
which	NULL
act	NULL
as	NULL
modular	NULL
domains	NULL
for	NULL
binding	NULL
and	NULL
activation	NULL
of	NULL
Stat3	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
An	NULL
advantage	NULL
of	NULL
the	NULL
chimeric	NULL
gp130	NULL
receptors	NULL
is	NULL
that	NULL
they	NULL
can	NULL
conceptually	NULL
be	NULL
used	NULL
to	NULL
stimulate	NULL
signal	NULL
transduction	NULL
by	NULL
gp130	NULL
without	NULL
interference	NULL
from	NULL
the	NULL
endogenous	NULL
IL-6R	NULL
.	NULL

These	NULL
effects	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
can	NULL
be	NULL
used	NULL
to	NULL
study	NULL
the	NULL
biological	NULL
effect	NULL
of	NULL
IL-6	NULL
on	NULL
B-cell	NULL
growth	NULL
or	NULL
differentiation	NULL
.	NULL

We	NULL
wished	NULL
to	NULL
determine	NULL
if	NULL
overexpression	NULL
of	NULL
the	NULL
chimeric	NULL
IL-6R	NULL
could	NULL
initiate	NULL
activation	NULL
of	NULL
the	NULL
JAK/Stat	NULL
pathway	NULL
in	NULL
©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
Chimeric	NULL
gp130	NULL
induces	NULL
Ig	NULL
M	NULL
in	NULL
a	NULL
Stat3-dependent	NULL
fashion	NULL
351	NULL
SKW6.4	NULL
cells	NULL
,	NULL
and	NULL
whether	NULL
these	NULL
biochemical	NULL
responses	NULL
could	NULL
be	NULL
related	NULL
to	NULL
an	NULL
IL-6-mediated	NULL
biological	NULL
response	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
namely	NULL
enhanced	NULL
IgM	NULL
synthesis	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
that	NULL
EGF	NULL
induced	NULL
IgM	NULL
production	NULL
in	NULL
SKW6.4	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
intact	NULL
EGF-gp130	NULL
chimeras	NULL
,	NULL
but	NULL
not	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
truncated	NULL
receptor	NULL
which	NULL
lacks	NULL
Stat3	NULL
binding	NULL
sites	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
this	NULL
response	NULL
correlates	NULL
with	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
intronic	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer	NULL
,	NULL
which	NULL
responds	NULL
in	NULL
a	NULL
Stat3-dependent	NULL
manner	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
IL-6-induced	NULL
B-cell	NULL
differentiation	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
IgM	NULL
production	NULL
,	NULL
may	NULL
be	NULL
controlled	NULL
by	NULL
Stat3	NULL
proteins	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Plasmids	NULL
Chimeric	NULL
EGF-gp130	NULL
receptor	NULL
constructs	NULL
were	NULL
generously	NULL
made	NULL
available	NULL
by	NULL
Regeneron	NULL
Pharmaceutical	NULL
(	NULL
Tarrytown	NULL
,	NULL
NY	NULL
)	NULL
and	NULL
consist	NULL
of	NULL
the	NULL
extracellular	NULL
domain	NULL
of	NULL
the	NULL
EGF	NULL
receptor	NULL
fused	NULL
to	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
gp130	NULL
.	NULL
``	NULL

'	NULL
The	NULL
IgH-enhancer	NULL
luciferase	NULL
construct	NULL
was	NULL
generated	NULL
by	NULL
subclo-ning	NULL
bases	NULL
1-450	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
region'*	NULL
into	NULL
the	NULL
pGL	NULL
,	NULL
Enhancer	NULL
vector	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

The	NULL
wild-type	NULL
STAT3	NULL
and	NULL
mutant	NULL
Stat3EE	NULL
constructs	NULL
were	NULL
generously	NULL
provided	NULL
by	NULL
Drs	NULL
James	NULL
E.	NULL
Darnell	NULL
Jr	NULL
and	NULL
Curt	NULL
Horvath	NULL
``	NULL
(	NULL
Rockefeller	NULL
University	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Transfection	NULL
of	NULL
cell	NULL
lines	NULL
The	NULL
human	NULL
myeloma	NULL
cell	NULL
line	NULL
AFIO	NULL
'	NULL
and	NULL
the	NULL
human	NULL
B-cell	NULL
line	NULL
SKW6.4°	NULL
have	NULL
been	NULL
previously	NULL
described	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI-1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
50	NULL
U/ml	NULL
penicillin	NULL
,	NULL
50	NULL
ug/ml	NULL
!	NULL

streptomycin	NULL
,	NULL
and	NULL
2	NULL
mm	NULL
L-gluta-mine	NULL
.	NULL

SKW6.4	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
the	NULL
chimeric	NULL
EGF-gp130	NULL
receptor	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
by	NULL
electroporation	NULL
in	NULL
0-4	NULL
cm	NULL
cuvettes	NULL
,	NULL
with	NULL
a	NULL
capacitance	NULL
of	NULL
950	NULL
uF	NULL
and	NULL
a	NULL
pulse	NULL
of	NULL
230	NULL
V.	NULL
Stable	NULL
transfectants	NULL
were	NULL
selected	NULL
and	NULL
subcloned	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
800	NULL
ug/ml	NULL
Geneticin	NULL
G418	NULL
(	NULL
Gibco-BRL	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
line	NULL
designated	NULL
as	NULL
A2	NULL
was	NULL
transfected	NULL
with	NULL
the	NULL
chimeric	NULL
receptor	NULL
containing	NULL
the	NULL
intact	NULL
gp130	NULL
tail	NULL
,	NULL
while	NULL
the	NULL
cell	NULL
line	NULL
designated	NULL
as	NULL
D4	NULL
was	NULL
transfected	NULL
with	NULL
a	NULL
truncated	NULL
chimeric	NULL
receptor	NULL
lacking	NULL
all	NULL
the	NULL
four	NULL
YXXQ	NULL
motifs	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
)	NULL
.	NULL

Cellular	NULL
stimulation	NULL
,	NULL
immunoprecipitations	NULL
and	NULL
Western	NULL
blots	NULL
Aliquots	NULL
of	NULL
5x	NULL
10°	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
100	NULL
U/ml	NULL
IL-6	NULL
or	NULL
100	NULL
ng	NULL
EGF	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
for	NULL
5	NULL
min	NULL
at	NULL
37°	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
50	NULL
mm	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7-4	NULL
,	NULL
150	NULL
mn	NULL
NaCl	NULL
,	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
(	NULL
v/v	NULL
)	NULL
,	NULL
1	NULL
mm	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
0-5	NULL
mM	NULL
ethylene	NULL
diamine	NULL
tetraacetic	NULL
acid	NULL
(	NULL
EDTA	NULL
)	NULL
,	NULL
10	NULL
mm	NULL
NaF	NULL
,	NULL
2	NULL
mM	NULL
phenyl	NULL
methylsulphonyl	NULL
fluoride	NULL
(	NULL
PMSF	NULL
)	NULL
,	NULL
10	NULL
ug/ml	NULL
leu-peptin	NULL
and	NULL
2	NULL
U/ml	NULL
aprotinin	NULL
.	NULL

Myc	NULL
immunoprecipitations	NULL
were	NULL
performed	NULL
by	NULL
incubating	NULL
500	NULL
ug	NULL
of	NULL
cell	NULL
lysates	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
9E10	NULL
antibody	NULL
(	NULL
Oncogene	NULL
Science	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
for	NULL
1	NULL
hr	NULL
at	NULL
4°	NULL
,	NULL
followed	NULL
by	NULL
preswollen	NULL
protein	NULL
A-Sepharose	NULL
beads	NULL
(	NULL
30	NULL
ul	NULL
)	NULL
.	NULL

Immunoprecipitates	NULL
or	NULL
80	NULL
ug	NULL
of	NULL
total	NULL
cell	NULL
lysates	NULL
were	NULL
boiled	NULL
in	NULL
2	NULL
x	NULL
sodium	NULL
dodecyl	NULL
sulphate	NULL
(	NULL
SDS	NULL
)	NULL
sample	NULL
buffer	NULL
and	NULL
were	NULL
resolved	NULL
by	NULL
10	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
electro-phoresis	NULL
(	NULL
PAGE	NULL
)	NULL
.	NULL

Proteins	NULL
were	NULL
transferred	NULL
to	NULL
Immobilon-P	NULL
membranes	NULL
and	NULL
the	NULL
membranes	NULL
were	NULL
probed	NULL
with	NULL
1	NULL
ug/ml	NULL
Anti-Myc	NULL
(	NULL
b	NULL
)	NULL
IP	NULL
:	NULL
a	NULL
S	NULL
<	NULL
4	NULL
n	NULL
(	NULL
a	NULL
)	NULL
A2	NULL
D4	NULL
108-Iss	NULL
Iss	NULL
s	NULL
102	NULL
1	NULL
6	NULL
Blot	NULL
:	NULL
A2	NULL
ese	NULL
.-	NULL
Cull	NULL
length	NULL
gp130	NULL
SKW	NULL
D4	NULL
94-	NULL
ase	NULL
-	NULL
-	NULL
Truncated	NULL
gp130	NULL
Anti-Myc	NULL
Figure	NULL
1	NULL
.	NULL

Expression	NULL
of	NULL
chimeric	NULL
EGF-gp130	NULL
receptors	NULL
in	NULL
stable	NULL
transfected	NULL
SKW6.4	NULL
cells	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
the	NULL
chimeric	NULL
gp130	NULL
receptors	NULL
.	NULL

The	NULL
chimeric	NULL
receptors	NULL
consist	NULL
of	NULL
the	NULL
extracellular	NULL
domain	NULL
of	NULL
the	NULL
EGF	NULL
receptor	NULL
linked	NULL
to	NULL
the	NULL
transmembrane	NULL
and	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
gp130	NULL
.	NULL

The	NULL
A2	NULL
receptor	NULL
represents	NULL
a	NULL
chimeric	NULL
receptor	NULL
in	NULL
which	NULL
the	NULL
intracellular	NULL
gp130	NULL
tail	NULL
is	NULL
intact	NULL
and	NULL
carries	NULL
four	NULL
modular	NULL
YXXQ	NULL
motifs	NULL
(	NULL
hatched	NULL
boxes	NULL
)	NULL
.	NULL

The	NULL
D4	NULL
receptor	NULL
represents	NULL
a	NULL
truncated	NULL
chimeric	NULL
receptor	NULL
such	NULL
that	NULL
all	NULL
four	NULL
YXXQ	NULL
motifs	NULL
are	NULL
deleted	NULL
.	NULL

Both	NULL
chimeric	NULL
receptors	NULL
express	NULL
a	NULL
myc-tag	NULL
at	NULL
their	NULL
C-terminus	NULL
(	NULL
circle	NULL
)	NULL
and	NULL
carry	NULL
an	NULL
intact	NULL
JAK	NULL
binding	NULL
site	NULL
at	NULL
their	NULL
membrane	NULL
proximal	NULL
domain	NULL
(	NULL
dark	NULL
boxes	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Anti-myc	NULL
immunoblot	NULL
showing	NULL
expression	NULL
of	NULL
chimeric	NULL
receptors	NULL
in	NULL
A2	NULL
and	NULL
D4	NULL
cells	NULL
.	NULL

Electroporation	NULL
was	NULL
used	NULL
to	NULL
transfect	NULL
10°	NULL
SKW6.4	NULL
cells	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
the	NULL
chimeric	NULL
EGF-gp130	NULL
receptor	NULL
constructs	NULL
.	NULL

Stable	NULL
transfectants	NULL
were	NULL
selected	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
800	NULL
ug/ml	NULL
Geneticin	NULL
G418	NULL
.	NULL

An	NULL
aliquot	NULL
of	NULL
5x	NULL
10°	NULL
parental	NULL
SKW6.4	NULL
cells	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
or	NULL
stable	NULL
transfectants	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
were	NULL
lysed	NULL
in	NULL
nonider-40	NULL
lysis	NULL
buffer	NULL
,	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
anti-myc	NULL
mAb	NULL
(	NULL
2	NULL
pl	NULL
)	NULL
.	NULL

The	NULL
immunoprecipitates	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
transferred	NULL
to	NULL
Immobilon-P	NULL
.	NULL

The	NULL
Western	NULL
blots	NULL
were	NULL
overlaid	NULL
with	NULL
1	NULL
ug/ml	NULL
of	NULL
anti-Myc	NULL
mAb	NULL
followed	NULL
by	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
HRP	NULL
)	NULL
-conjugated	NULL
sheep	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
,	NULL
and	NULL
developed	NULL
by	NULL
enhanced	NULL
chemiluminesce	NULL
(	NULL
ECL	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

©	NULL
1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
350-357	NULL
352	NULL
M.	NULL
Faris	NULL
et	NULL
al	NULL
.	NULL

4G1O0	NULL
(	NULL
UBI	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
1	NULL
ug/ml	NULL
anti-Myc	NULL
or	NULL
anti-phospho-Stat3	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
were	NULL
detected	NULL
by	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
HRP	NULL
)	NULL
-sheep	NULL
anti-mouse	NULL
and	NULL
blots	NULL
were	NULL
developed	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

'*	NULL
In	NULL
short	NULL
,	NULL
the	NULL
double-stranded	NULL
oligonucleotide	NULL
used	NULL
,	NULL
S5-GTCGACATTTCCCGTAAAT-3	NULL
'	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
sis-inducible	NULL
element	NULL
(	NULL
hSIE	NULL
)	NULL
from	NULL
the	NULL
c-fos	NULL
promoter	NULL
,	NULL
was	NULL
end-labelled	NULL
using	NULL
Klenow	NULL
reaction	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
«	NULL
``	NULL
°P-dCTP	NULL
(	NULL
Dupont-NEN	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Whole	NULL
cellular	NULL
extract	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
binding	NULL
buffer	NULL
(	NULL
20	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7-9	NULL
,	NULL
4	NULL
%	NULL
Ficoll	NULL
,	NULL
1	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
40	NULL
mm	NULL
KCl	NULL
,	NULL
0-1	NULL
mm	NULL
EGTA	NULL
,	NULL
0-4	NULL
mm	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
30	NULL
ug/ml	NULL
poly	NULL
dI	NULL
:	NULL
dC	NULL
and	NULL
1	NULL
mg/ml	NULL
!	NULL

salmon	NULL
sperm	NULL
DNA	NULL
)	NULL
and	NULL
12	NULL
ng	NULL
of	NULL
radio-labelled	NULL
probe	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
and	NULL
separated	NULL
on	NULL
5	NULL
%	NULL
acrylamide	NULL
gels	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
autoradiographed	NULL
.	NULL

Ig	NULL
M	NULL
production	NULL
Parental	NULL
and	NULL
transfected	NULL
SKW6.4	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
4	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
media	NULL
alone	NULL
,	NULL
100	NULL
U/ml	NULL
IL-6	NULL
or	NULL
100	NULL
ng/ml	NULL
EGF	NULL
.	NULL

Supernatants	NULL
were	NULL
collected	NULL
and	NULL
assayed	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
IgM	NULL
by	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
'	NULL

''	NULL
In	NULL
short	NULL
,	NULL
cell	NULL
supernatants	NULL
were	NULL
incubated	NULL
for	NULL
4h	NULL
in	NULL
Costar	NULL
ELISA	NULL
plates	NULL
previously	NULL
coated	NULL
with	NULL
1:1000	NULL
mouse	NULL
anti-hlgM	NULL
(	NULL
Tago	NULL
,	NULL
Burlingham	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Goat	NULL
anti-human	NULL
IgM	NULL
coupled	NULL
to	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
Tago	NULL
,	NULL
Burlingham	NULL
,	NULL
CA	NULL
)	NULL
was	NULL
added	NULL
for	NULL
2	NULL
hr	NULL
at	NULL
room	NULL
tempera-ture	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
initiated	NULL
with	NULL
p-nitrophenylphosphate	NULL
substrate	NULL
and	NULL
the	NULL
absorbance	NULL
was	NULL
read	NULL
at	NULL
405	NULL
nm	NULL
.	NULL

Each	NULL
experiment	NULL
was	NULL
performed	NULL
in	NULL
triplicate	NULL
,	NULL
and	NULL
included	NULL
a	NULL
standard	NULL
curve	NULL
consisting	NULL
of	NULL
serial	NULL
dilutions	NULL
of	NULL
purified	NULL
IgM	NULL
(	NULL
Tago	NULL
,	NULL
Burlingham	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Ig	NULL
H-enhancer	NULL
luciferase	NULL
activity	NULL
SKW6.4	NULL
or	NULL
AF1O	NULL
cells	NULL
(	NULL
3	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
as	NULL
described	NULL
above	NULL
with	NULL
8	NULL
ug	NULL
of	NULL
IgH-enhancer	NULL
luciferase	NULL
reporter	NULL
plasmid	NULL
.	NULL

In	NULL
cotransfection	NULL
assays	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
empty	NULL
vector	NULL
or	NULL
10	NULL
ug	NULL
constructs	NULL
encoding	NULL
for	NULL
wild	NULL
type	NULL
Stat3	NULL
or	NULL
Stat3EE	NULL
were	NULL
transfected	NULL
simultaneously	NULL
with	NULL
the	NULL
reporter	NULL
plasmid	NULL
.	NULL

Samples	NULL
were	NULL
pooled	NULL
and	NULL
allowed	NULL
to	NULL
recover	NULL
for	NULL
6	NULL
hr	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
14	NULL
hr	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
,	NULL
lysed	NULL
in	NULL
luciferase	NULL
buffer	NULL
(	NULL
Analytical	NULL
Luminescence	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
)	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
90	NULL
ug	NULL
of	NULL
proteins	NULL
in	NULL
a	NULL
Monolight	NULL
2010	NULL
luminometer	NULL
(	NULL
Analytical	NULL
Luminescence	NULL
)	NULL
.	NULL

Inter-sample	NULL
variation	NULL
in	NULL
efficiency	NULL
of	NULL
transfection	NULL
was	NULL
monitored	NULL
by	NULL
cotransfection	NULL
with	NULL
5	NULL
ug	NULL
pSV	NULL
BGal	NULL
reporter	NULL
plasmid	NULL
(	NULL
Promega	NULL
Corp	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
,	NULL
and	NULL
BGal	NULL
activity	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
galactosidase	NULL
assay	NULL
kit	NULL
from	NULL
Promega	NULL
(	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

RESULTS	NULL
Stable	NULL
transfection	NULL
of	NULL
chimeric	NULL
IL-6	NULL
receptors	NULL
in	NULL
SKW6.4	NULL
cells	NULL
SKW6.4	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
expression	NULL
constructs	NULL
encoding	NULL
epitope-tagged	NULL
chimeric	NULL
gp130	NULL
proteins	NULL
consisting	NULL
of	NULL
the	NULL
extracellular	NULL
domain	NULL
of	NULL
the	NULL
EGF	NULL
receptor	NULL
linked	NULL
to	NULL
the	NULL
full-length	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
gp130	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
)	NULL
.	NULL
``	NULL

The	NULL
cyto-	NULL
plasmic	NULL
tail	NULL
of	NULL
gp130	NULL
exhibits	NULL
four	NULL
YXXQ	NULL
motifs	NULL
necessary	NULL
for	NULL
signal	NULL
transduction	NULL
``	NULL
(	NULL
Fig	NULL
.	NULL

la	NULL
)	NULL
.	NULL

To	NULL
delineate	NULL
further	NULL
the	NULL
significance	NULL
of	NULL
these	NULL
motifs	NULL
in	NULL
IL-6-induced	NULL
B-lymphocyte	NULL
differentiation	NULL
,	NULL
another	NULL
aliquot	NULL
of	NULL
SKW6.4	NULL
cells	NULL
was	NULL
stably	NULL
transfected	NULL
with	NULL
a	NULL
chimeric	NULL
receptor	NULL
from	NULL
which	NULL
all	NULL
four	NULL
YXXQ	NULL
motifs	NULL
were	NULL
deleted	NULL
(	NULL
Fig	NULL
.	NULL

1a	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
subcloned	NULL
by	NULL
limiting	NULL
dilution	NULL
and	NULL
selected	NULL
with	NULL
geneticin	NULL
at	NULL
800	NULL
ug/ml	NULL
for	NULL
4	NULL
weeks	NULL
.	NULL

The	NULL
cell	NULL
line	NULL
transfected	NULL
with	NULL
the	NULL
intact	NULL
gp130	NULL
cytoplasmic	NULL
tail	NULL
domain	NULL
was	NULL
designated	NULL
A2	NULL
,	NULL
while	NULL
the	NULL
cell	NULL
line	NULL
containing	NULL
the	NULL
truncated	NULL
cytoplasmic	NULL
domain	NULL
was	NULL
designated	NULL
D4	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
expression	NULL
of	NULL
chimeric	NULL
receptors	NULL
in	NULL
transfected	NULL
SK	NULL
W6.4	NULL
cells	NULL
,	NULL
we	NULL
used	NULL
the	NULL
myc-tag	NULL
at	NULL
the	NULL
carboxyl-terminus	NULL
of	NULL
the	NULL
construct	NULL
to	NULL
immunoprecipitate	NULL
the	NULL
chimeric	NULL
receptors	NULL
.	NULL

Western	NULL
blotting	NULL
of	NULL
the	NULL
anti-myc	NULL
immunoprecipitates	NULL
revealed	NULL
that	NULL
while	NULL
no	NULL
chimeric	NULL
receptors	NULL
were	NULL
detectable	NULL
in	NULL
untransfected	NULL
ceils	NULL
,	NULL
full	NULL
length	NULL
as	NULL
well	NULL
as	NULL
truncated	NULL
chimeric	NULL
EGF-gp130	NULL
receptors	NULL
were	NULL
discernible	NULL
in	NULL
SKW6.4	NULL
transfectants	NULL
(	NULL
Fig	NULL
.	NULL

1b	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Engagement	NULL
of	NULL
gp130	NULL
chimeras	NULL
by	NULL
EGF	NULL
induces	NULL
IgM	NULL
secretion	NULL
in	NULL
stable	NULL
transfected	NULL
SKW6.4	NULL
cells	NULL
SKW6.4	NULL
is	NULL
an	NULL
Ig	NULL
M-secreting	NULL
B-cell	NULL
line	NULL
in	NULL
which	NULL
IgM	NULL
secretion	NULL
can	NULL
be	NULL
enhanced	NULL
by	NULL
IL-6.°	NULL
We	NULL
made	NULL
use	NULL
of	NULL
this	NULL
characteristic	NULL
to	NULL
ask	NULL
whether	NULL
the	NULL
chimeric	NULL
IL-6R	NULL
can	NULL
generate	NULL
a	NULL
biological	NULL
response	NULL
in	NULL
transfected	NULL
cells	NULL
.	NULL

Parental	NULL
SKW6.4	NULL
and	NULL
A2	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
4	NULL
days	NULL
in	NULL
media	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-6	NULL
,	NULL
EGF	NULL
,	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
both	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
collected	NULL
and	NULL
IgM	NULL
production	NULL
was	NULL
measured	NULL
by	NULL
ELISA	NULL
.	NULL

Figure	NULL
2	NULL
shows	NULL
that	NULL
IL-6	NULL
increased	NULL
IgM	NULL
production	NULL
in	NULL
both	NULL
parental	NULL
SKW6.4	NULL
and	NULL
A2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
while	NULL
EGF	NULL
treatment	NULL
induced	NULL
a	NULL
4-5-fold	NULL
increase	NULL
in	NULL
IgM	NULL
production	NULL
in	NULL
A2	NULL
cells	NULL
,	NULL
no	NULL
significant	NULL
response	NULL
was	NULL
obtained	NULL
in	NULL
parental	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Costimulation	NULL
of	NULL
A2	NULL
cells	NULL
with	NULL
IL-6	NULL
and	NULL
EGF	NULL
resulted	NULL
in	NULL
an	NULL
additive	NULL
effect	NULL
,	NULL
generating	NULL
a	NULL
10-4-fold	NULL
increase	NULL
in	NULL
IgM	NULL
production	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Costimulation	NULL
of	NULL
parental	NULL
SKW6.4	NULL
cells	NULL
with	NULL
IL-6	NULL
and	NULL
EGF	NULL
failed	NULL
to	NULL
produce	NULL
an	NULL
additive	NULL
response	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

These	NULL
results	NULL
can	NULL
not	NULL
be	NULL
explained	NULL
by	NULL
differences	NULL
in	NULL
the	NULL
rate	NULL
of	NULL
cellular	NULL
proliferation	NULL
,	NULL
since	NULL
SKW6.4	NULL
cells	NULL
fail	NULL
to	NULL
proliferate	NULL
in	NULL
response	NULL
to	NULL
IL-6	NULL
treatment	NULL
.	NULL
``	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
failed	NULL
to	NULL
observe	NULL
a	NULL
difference	NULL
in	NULL
cell	NULL
number	NULL
or	NULL
viability	NULL
in	NULL
stimulated	NULL
and	NULL
control	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
a	NULL
second	NULL
set	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
compared	NULL
IgM	NULL
production	NULL
in	NULL
A2	NULL
and	NULL
D4	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

IL-6	NULL
induced	NULL
a	NULL
five-	NULL
to	NULL
sixfold	NULL
increase	NULL
in	NULL
IgM	NULL
production	NULL
in	NULL
parental	NULL
as	NULL
well	NULL
as	NULL
in	NULL
transfected	NULL
SK	NULL
W6.4	NULL
cell	NULL
lines	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

While	NULL
A2	NULL
cells	NULL
demonstrated	NULL
a	NULL
threefold	NULL
increase	NULL
in	NULL
IgM	NULL
secretion	NULL
upon	NULL
treatment	NULL
with	NULL
EGF	NULL
,	NULL
no	NULL
enhancement	NULL
of	NULL
IgM	NULL
production	NULL
was	NULL
seen	NULL
with	NULL
this	NULL
stimulus	NULL
in	NULL
parental	NULL
or	NULL
D4	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
in	NULL
the	NULL
initiation	NULL
of	NULL
this	NULL
biological	NULL
response	NULL
,	NULL
SKW6.4	NULL
cells	NULL
require	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
intact	NULL
gp130	NULL
cytoplasmic	NULL
domain	NULL
.	NULL

Chimeric	NULL
A2	NULL
but	NULL
not	NULL
D4	NULL
receptors	NULL
induce	NULL
discernible	NULL
effects	NULL
on	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
including	NULL
the	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
Stat3	NULL
We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
IL-6	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
gp130.°	NULL
This	NULL
effect	NULL
is	NULL
likely	NULL
mediated	NULL
by	NULL
receptor-associated	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
(	NULL
PTK	NULL
)	NULL
,	NULL
JAK1	NULL
and	NULL
©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
350-357	NULL
Chimeric	NULL
gp130	NULL
induces	NULL
Ig	NULL
M	NULL
in	NULL
a	NULL
Stat3-dependent	NULL
fashion	NULL
353	NULL
Medi	NULL
(	NULL
10-4	NULL
)	NULL
``	NULL
|	NULL
a	NULL
``	NULL
fem	NULL
©	NULL
EGF	NULL
e_	NULL
EGF	NULL
+	NULL
IL-6	NULL
10	NULL
&	NULL
.6	NULL
8	NULL
s	NULL
C	NULL
o	NULL
a	NULL
.	NULL

3	NULL
J	NULL
(	NULL
5-3	NULL
)	NULL
(	NULL
4-5	NULL
)	NULL
a	NULL
6	NULL
9	NULL
@	NULL
®	NULL
5	NULL
€	NULL
o	NULL
4	NULL
[	NULL
«	NULL
]	NULL
LL	NULL
2	NULL
o	NULL
1	NULL
SWK	NULL
A2	NULL
Figure	NULL
2	NULL
.	NULL

IL-6	NULL
and	NULL
EGF	NULL
induces	NULL
IgM	NULL
production	NULL
in	NULL
A2	NULL
cells	NULL
as	NULL
determined	NULL
by	NULL
ELISA	NULL
.	NULL

SKW6.4	NULL
and	NULL
A2	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10*/ml	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
media	NULL
alone	NULL
,	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
U/ml	NULL
IL-6	NULL
,	NULL
100	NULL
ng/ml	NULL
EGF	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
100	NULL
U/ml	NULL
IL-6	NULL
+100	NULL
ng/ml	NULL
EGF	NULL
for	NULL
4	NULL
days	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
collected	NULL
and	NULL
IgM	NULL
production	NULL
was	NULL
measured	NULL
in	NULL
triplicate	NULL
by	NULL
ELISA	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
means	NULL
and	NULL
standard	NULL
deviations	NULL
from	NULL
three	NULL
experiments	NULL
.	NULL

Table	NULL
1	NULL
.	NULL

Fold	NULL
increase	NULL
in	NULL
IgM	NULL
production	NULL
by	NULL
parental	NULL
SKW6.4	NULL
cells	NULL
and	NULL
SKW6.4	NULL
transfectants	NULL
expressing	NULL
chimeric	NULL
gp130	NULL
receptors	NULL
Treatment	NULL
Cell	NULL
line	NULL
IL-6	NULL
EGF	NULL
SKW6.4*	NULL
6:0	NULL
+0-59	NULL
1:0	NULL
+0-20	NULL
A2	NULL
5:5+045	NULL
3-0	NULL
+0-81	NULL
D4	NULL
59	NULL
+0-28	NULL
0-9	NULL
+0-03	NULL
*Control	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
media	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-6	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
or	NULL
EGF	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
for	NULL
4	NULL
days	NULL
.	NULL

IgM	NULL
secretion	NULL
was	NULL
measured	NULL
by	NULL
ELISA	NULL
.	NULL

The	NULL
baseline	NULL
amount	NULL
of	NULL
IgM	NULL
produced	NULL
by	NULL
untreated	NULL
SKW6.4	NULL
was	NULL
463	NULL
ng/ml	NULL
,	NULL
500	NULL
ng/ml	NULL
for	NULL
A2	NULL
,	NULL
and	NULL
447	NULL
ng/ml	NULL
for	NULL
D4	NULL
.	NULL

The	NULL
fold	NULL
increase	NULL
was	NULL
calculated	NULL
for	NULL
each	NULL
population	NULL
based	NULL
on	NULL
these	NULL
quantifications	NULL
.	NULL

The	NULL
values	NULL
in	NULL
this	NULL
table	NULL
represent	NULL
the	NULL
means	NULL
and	NULL
standard	NULL
deviations	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

JAK2	NULL
,	NULL
which	NULL
associate	NULL
with	NULL
the	NULL
membrane	NULL
proximal	NULL
domain	NULL
of	NULL
gp130	NULL
'	NULL
%	NULL
``	NULL
``	NULL
%	NULL
``	NULL
``	NULL
To	NULL
determine	NULL
whether	NULL
the	NULL
chimeric	NULL
EGF-gp130	NULL
receptors	NULL
induce	NULL
biochemical	NULL
signals	NULL
in	NULL
stably	NULL
transfected	NULL
SKW4.6	NULL
cells	NULL
,	NULL
epitope-tagged	NULL
chimeric	NULL
gp130	NULL
receptors	NULL
were	NULL
immunoprecipitated	NULL
from	NULL
control	NULL
and	NULL
EGF-treated	NULL
cells	NULL
and	NULL
the	NULL
immunoprecipitates	NULL
were	NULL
analysed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
.	NULL

In	NULL
A2	NULL
,	NULL
but	NULL
not	NULL
D4	NULL
,	NULL
cells	NULL
,	NULL
we	NULL
observed	NULL
constitutive	NULL
phosphorylation	NULL
of	NULL
chimeric	NULL
gp130	NULL
which	NULL
was	NULL
further	NULL
increased	NULL
upon	NULL
treatment	NULL
with	NULL
EGF	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Along	NULL
similar	NULL
lines	NULL
,	NULL
EGF	NULL
induced	NULL
increased	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
JAK	NULL
1	NULL
in	NULL
A2	NULL
but	NULL
not	NULL
D4	NULL
cells	NULL
,	NULL
while	NULL
JAK2	NULL
was	NULL
constitutively	NULL
phos-	NULL
©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
350-357	NULL
phorylated	NULL
in	NULL
SKW6.4	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
neither	NULL
endogenous	NULL
gp130	NULL
nor	NULL
JAK1	NULL
were	NULL
phosphorylated	NULL
in	NULL
unstimulated	NULL
SKW6.4	NULL
cells	NULL
.	NULL

IL-6	NULL
is	NULL
also	NULL
known	NULL
to	NULL
activate	NULL
the	NULL
cytoplasmic	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
,	NULL
Stat3	NULL
,	NULL
by	NULL
inducing	NULL
its	NULL
phosphorylation	NULL
on	NULL
tyrosine	NULL
residues	NULL
.	NULL

``	NULL
``	NULL
~	NULL
``	NULL
We	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
chimeric	NULL
EGF-gp130	NULL
receptors	NULL
on	NULL
Stat3	NULL
tyrosine	NULL
phosphorylation	NULL
.	NULL

Total	NULL
cell	NULL
lysates	NULL
from	NULL
control	NULL
and	NULL
EGF-stimulated	NULL
cells	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
overlaid	NULL
with	NULL
antiserum	NULL
raised	NULL
against	NULL
the	NULL
consensus	NULL
tyrosine	NULL
phosphorylation	NULL
site	NULL
of	NULL
Stat3	NULL
(	NULL
Y¥705	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

As	NULL
a	NULL
positive	NULL
control	NULL
we	NULL
used	NULL
AFIO	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
inducing	NULL
the	NULL
phosphorylation	NULL
of	NULL
the	NULL
89000	NULL
MW	NULL
Stat3	NULL
protein	NULL
in	NULL
AFIO	NULL
cells	NULL
,	NULL
IL-6	NULL
treatment	NULL
also	NULL
induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
an	NULL
83000	NULL
MW	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
upper	NULL
panel	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

This	NULL
may	NULL
be	NULL
a	NULL
splice	NULL
variant	NULL
of	NULL
Stat3	NULL
which	NULL
has	NULL
been	NULL
characterized	NULL
as	NULL
Stat3	NULL
$	NULL
.	NULL
``	NULL

''	NULL
Figure	NULL
3	NULL
shows	NULL
that	NULL
while	NULL
EGF	NULL
did	NULL
not	NULL
induce	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
p89	NULL
in	NULL
parental	NULL
SKW6.4	NULL
cells	NULL
,	NULL
this	NULL
ligand	NULL
did	NULL
induce	NULL
phosphorylation	NULL
of	NULL
Stat3	NULL
in	NULL
A2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
upper	NULL
panel	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

No	NULL
phosphorylation	NULL
of	NULL
Stat3	NULL
was	NULL
seen	NULL
in	NULL
D4	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
were	NULL
not	NULL
due	NULL
to	NULL
dissimilar	NULL
amounts	NULL
of	NULL
Stat3	NULL
,	NULL
since	NULL
equal	NULL
amounts	NULL
of	NULL
Stat3	NULL
proteins	NULL
could	NULL
be	NULL
visualized	NULL
in	NULL
Stat3	NULL
immunoblots	NULL
of	NULL
total	NULL
cell	NULL
lysates	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
of	NULL
Stat	NULL
proteins	NULL
results	NULL
in	NULL
their	NULL
AF10	NULL
SKW	NULL
A2	NULL
ﬁlo	NULL
LLL	NULL
LL	NULL
o	NULL
=o	NULL
8	NULL
o	NULL
&	NULL
Mw	NULL
x	NULL
108	NULL
108-we	NULL
»	NULL
-	NULL
Phospho-Stat3	NULL
84-	NULL
.	NULL

LJ	NULL
67-=	NULL
«	NULL
aur	NULL
-	NULL
eu	NULL
P	NULL
S5-1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Blot	NULL
:	NULL
Anti-Phospho-Stat3	NULL
Ei	NULL
-a	NULL
Stat3	NULL
84-	NULL
a	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Blot	NULL
:	NULL
Anti-Stat3	NULL
Figure	NULL
3	NULL
.	NULL

Phosphorylation	NULL
of	NULL
Stat3	NULL
proteins	NULL
in	NULL
transfected	NULL
A2	NULL
cells	NULL
.	NULL

Aliquots	NULL
of	NULL
5x	NULL
10°	NULL
AFIO	NULL
,	NULL
parental	NULL
SKW6.4	NULL
and	NULL
A2	NULL
cells	NULL
were	NULL
stimulated	NULL
in	NULL
media	NULL
alone	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
3	NULL
and	NULL
5	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
U/ml	NULL
IL-6	NULL
(	NULL
lane2	NULL
)	NULL
or	NULL
100	NULL
ng/ml	NULL
EGF	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Total	NULL
cell	NULL
lysates	NULL
were	NULL
resolved	NULL
by	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
transferred	NULL
to	NULL
Immobilon-P	NULL
.	NULL

In	NULL
the	NULL
upper	NULL
panel	NULL
,	NULL
the	NULL
blot	NULL
was	NULL
overlaid	NULL
with	NULL
1	NULL
:	NULL
1000	NULL
of	NULL
antiserum	NULL
raised	NULL
against	NULL
the	NULL
phosphorylation	NULL
site	NULL
of	NULL
Stat3	NULL
(	NULL
Y705	NULL
)	NULL
(	NULL
New	NULL
England	NULL
BioLabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
developed	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
.	NULL

In	NULL
the	NULL
lower	NULL
panel	NULL
,	NULL
the	NULL
blot	NULL
was	NULL
overlaid	NULL
with	NULL
01	NULL
ug/ml	NULL
of	NULL
anti	NULL
Stat3	NULL
Ab	NULL
,	NULL
followed	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
.	NULL

354	NULL
M.	NULL
Faris	NULL
et	NULL
al	NULL
.	NULL

dimerization	NULL
and	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
where	NULL
they	NULL
bind	NULL
to	NULL
specific	NULL
DNA	NULL
response	NULL
elements	NULL
.	NULL
``	NULL

In	NULL
particular	NULL
,	NULL
activated	NULL
Stat3	NULL
is	NULL
known	NULL
to	NULL
associate	NULL
with	NULL
interferon-y	NULL
(	NULL
IFN-y	NULL
)	NULL
-activated	NULL
sites	NULL
(	NULL
GAS	NULL
)	NULL
.	NULL

Utilizing	NULL
EMSA	NULL
,	NULL
we	NULL
measured	NULL
the	NULL
ability	NULL
of	NULL
cell	NULL
lysates	NULL
from	NULL
control	NULL
and	NULL
treated	NULL
cells	NULL
to	NULL
form	NULL
DNA	NULL
binding	NULL
complexes	NULL
with	NULL
a	NULL
GAS	NULL
,	NULL
the	NULL
hSIE	NULL
of	NULL
the	NULL
c-fos	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

IL-6	NULL
treated	NULL
AFIO	NULL
cells	NULL
were	NULL
used	NULL
as	NULL
positive	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
the	NULL
A2	NULL
cells	NULL
,	NULL
expressing	NULL
the	NULL
full-length	NULL
chimeric	NULL
receptor	NULL
,	NULL
with	NULL
EGF	NULL
induced	NULL
the	NULL
mobility	NULL
shift	NULL
of	NULL
the	NULL
labelled	NULL
hSIE	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
this	NULL
binding	NULL
reaction	NULL
was	NULL
confirmed	NULL
by	NULL
abrogation	NULL
of	NULL
the	NULL
gel	NULL
shift	NULL
with	NULL
excess	NULL
unlabelled	NULL
hSIE	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
preincu-bation	NULL
of	NULL
cell	NULL
lysates	NULL
with	NULL
anti-Stat3	NULL
antibody	NULL
resulted	NULL
in	NULL
a	NULL
hypomobility	NULL
shift	NULL
of	NULL
the	NULL
protein/DNA	NULL
complex	NULL
in	NULL
EGF-treated	NULL
A2	NULL
cells	NULL
,	NULL
confirming	NULL
the	NULL
presence	NULL
of	NULL
Stat3	NULL
in	NULL
that	NULL
complex	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
EGF	NULL
failed	NULL
to	NULL
induced	NULL
a	NULL
shift	NULL
complex	NULL
in	NULL
parental	NULL
SKW6.4	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
,	NULL
or	NULL
in	NULL
D4	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
data	NULL
show	NULL
that	NULL
the	NULL
chimeric	NULL
EGF-gp130	NULL
receptor	NULL
which	NULL
contains	NULL
an	NULL
intact	NULL
cytoplasmic	NULL
tail	NULL
is	NULL
able	NULL
to	NULL
transduce	NULL
biochemical	NULL
signals	NULL
,	NULL
including	NULL
activation	NULL
of	NULL
the	NULL
JAK/Stat	NULL
pathway	NULL
.	NULL

Engagement	NULL
of	NULL
gp130	NULL
induces	NULL
activity	NULL
of	NULL
an	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer-reporter	NULL
construct	NULL
in	NULL
AF10	NULL
and	NULL
transfected	NULL
SKW6.4	NULL
cells	NULL
A	NULL
critical	NULL
question	NULL
is	NULL
whether	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
chimeric	NULL
gp130	NULL
receptor	NULL
on	NULL
IgM	NULL
production	NULL
in	NULL
A2	NULL
cells	NULL
could	NULL
be	NULL
explained	NULL
by	NULL
a	NULL
genetic	NULL
element	NULL
in	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
locus	NULL
.	NULL

Probe	NULL
:	NULL
hSIE	NULL
I	NULL
1	NULL
2	NULL
0	NULL
z	NULL
e	NULL
LL	NULL
x	NULL
OU	NULL
LL	NULL
-	NULL
OU	NULL
<	NULL
n	NULL
<	NULL
<	NULL
<	NULL
w	NULL
LL	NULL
L.	NULL
w	NULL
j	NULL
L.	NULL
Treatment	NULL
s	NULL
2	NULL
s	NULL
&	NULL
o	NULL
9	NULL
L	NULL
9	NULL
Unlabelled	NULL
SIE	NULL
k	NULL
ok	NULL
ok	NULL
%	NULL
+o	NULL
+	NULL
#	NULL
#	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
°	NULL
6	NULL
7	NULL
8	NULL
Figure	NULL
4	NULL
.	NULL

EGF	NULL
induces	NULL
hSIE	NULL
binding	NULL
mobility	NULL
shift	NULL
complexes	NULL
in	NULL
A2	NULL
cells	NULL
.	NULL

AFIO	NULL
,	NULL
SKW6.4	NULL
and	NULL
A2	NULL
cells	NULL
(	NULL
5x	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
media	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
U/ml	NULL
IL-6	NULL
or	NULL
100	NULL
ng/ml	NULL
EGF	NULL
as	NULL
indicated	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Twenty	NULL
micrograms	NULL
of	NULL
total	NULL
cell	NULL
lysates	NULL
were	NULL
added	NULL
to	NULL
*P-labelled	NULL
hSIE	NULL
oligonucleotides	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
lanes	NULL
1-6	NULL
)	NULL
of	NULL
10-fold	NULL
excess	NULL
unlabelled	NULL
hSIE	NULL
.	NULL

The	NULL
complexes	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
5	NULL
%	NULL
PAGE	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
dryed	NULL
and	NULL
autoradiographed	NULL
for	NULL
16	NULL
hours	NULL
.	NULL

Since	NULL
IL-6	NULL
is	NULL
known	NULL
to	NULL
enhance	NULL
immunoglobulin	NULL
synthesis	NULL
as	NULL
a	NULL
result	NULL
of	NULL
transcriptional	NULL
activation	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
without	NULL
isotype	NULL
specificity	NULL
,	NULL
``	NULL
°	NULL
we	NULL
considered	NULL
genetic	NULL
response	NULL
elements	NULL
that	NULL
conform	NULL
to	NULL
this	NULL
characteristic	NULL
.	NULL

A	NULL
genetic	NULL
element	NULL
that	NULL
participates	NULL
in	NULL
isotype-independent	NULL
enhancement	NULL
at	NULL
the	NULL
heavy	NULL
chain	NULL
locus	NULL
is	NULL
the	NULL
so-called	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer	NULL
(	NULL
IgH-enhancer	NULL
)	NULL
,	NULL
which	NULL
is	NULL
an	NULL
intronic	NULL
sequence	NULL
immediately	NULL
upstream	NULL
of	NULL
the	NULL
p	NULL
switch	NULL
region	NULL
.	NULL

'**	NULL
``	NULL
After	NULL
V-D-J	NULL
rearrangement	NULL
,	NULL
this	NULL
intron	NULL
separating	NULL
J4	NULL
and	NULL
Cu	NULL
becomes	NULL
a	NULL
part	NULL
of	NULL
all	NULL
productive	NULL
arrangements	NULL
.	NULL
``	NULL

The	NULL
Igu	NULL
enhancer	NULL
is	NULL
a	NULL
complex	NULL
regulatory	NULL
element	NULL
that	NULL
contains	NULL
binding	NULL
sites	NULL
for	NULL
many	NULL
different	NULL
DNA-binding	NULL
proteins	NULL
.	NULL

``	NULL
°~	NULL
'	NULL
In	NULL
order	NULL
to	NULL
define	NULL
whether	NULL
gp130	NULL
may	NULL
affect	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
,	NULL
we	NULL
constructed	NULL
a	NULL
reporter	NULL
gene	NULL
in	NULL
which	NULL
the	NULL
first	NULL
450	NULL
nucleotides	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
were	NULL
linked	NULL
to	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
in	NULL
the	NULL
pGL2	NULL
vector	NULL
(	NULL
see	NULL
the	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

The	NULL
construct	NULL
was	NULL
introduced	NULL
by	NULL
transient	NULL
transfection	NULL
into	NULL
parental	NULL
and	NULL
EGF-gp130	NULL
expressing	NULL
SK	NULL
W6.4	NULL
cell	NULL
lines	NULL
.	NULL

For	NULL
comparison	NULL
,	NULL
the	NULL
IgH-enhancer	NULL
luciferase	NULL
construct	NULL
was	NULL
also	NULL
introduced	NULL
into	NULL
AFIO	NULL
cells	NULL
.	NULL
``	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
IL-6	NULL
or	NULL
EGF	NULL
for	NULL
14	NULL
hr	NULL
,	NULL
lysed	NULL
and	NULL
analysed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

Cotransfection	NULL
of	NULL
a	NULL
gal	NULL
construct	NULL
was	NULL
used	NULL
to	NULL
correct	NULL
for	NULL
the	NULL
efficiency	NULL
of	NULL
transfection	NULL
.	NULL

IL-6	NULL
induced	NULL
a	NULL
3:2-fold	NULL
increase	NULL
in	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IgH-enhancer	NULL
in	NULL
AFIO	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5a	NULL
)	NULL
,	NULL
which	NULL
is	NULL
comparable	NULL
to	NULL
the	NULL
magnitude	NULL
of	NULL
expression	NULL
of	NULL
an	NULL
Ign	NULL
reporter	NULL
gene	NULL
in	NULL
haematopoietic	NULL
cells	NULL
.	NULL
``	NULL

Compared	NULL
with	NULL
untreated	NULL
cells	NULL
,	NULL
treatment	NULL
with	NULL
IL-6	NULL
increased	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IgH-enhancer	NULL
3:1-fold	NULL
in	NULL
A2	NULL
cell	NULL
line	NULL
,	NULL
while	NULL
treatment	NULL
with	NULL
EGF	NULL
resulted	NULL
in	NULL
a	NULL
4-8-fold	NULL
increase	NULL
in	NULL
IgH	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

Sa	NULL
)	NULL
.	NULL

The	NULL
magnitude	NULL
of	NULL
this	NULL
response	NULL
compares	NULL
favourably	NULL
to	NULL
the	NULL
4-5-fold	NULL
enhancement	NULL
of	NULL
IgM	NULL
production	NULL
by	NULL
EGF	NULL
in	NULL
A2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
a	NULL
separate	NULL
experiment	NULL
,	NULL
treatment	NULL
of	NULL
A2	NULL
cells	NULL
with	NULL
both	NULL
IL-6	NULL
and	NULL
EGF	NULL
showed	NULL
an	NULL
additive	NULL
effect	NULL
on	NULL
the	NULL
IgH-enhancer	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5a	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
its	NULL
stimulating	NULL
effect	NULL
in	NULL
A2	NULL
cells	NULL
,	NULL
EGF	NULL
failed	NULL
to	NULL
induce	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IgH-enhancer	NULL
reporter	NULL
in	NULL
parental	NULL
SKW6.4	NULL
(	NULL
Fig	NULL
.	NULL

Sa	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
IL-6	NULL
did	NULL
,	NULL
however	NULL
,	NULL
induce	NULL
a	NULL
2-2-fold	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
in	NULL
parental	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

Sa	NULL
)	NULL
.	NULL

An	NULL
important	NULL
question	NULL
is	NULL
whether	NULL
the	NULL
IgH-enhancer	NULL
is	NULL
regulated	NULL
by	NULL
Stat3	NULL
in	NULL
response	NULL
to	NULL
engagement	NULL
of	NULL
endogenous	NULL
or	NULL
transfected	NULL
IL-6	NULL
receptors	NULL
.	NULL

If	NULL
such	NULL
a	NULL
functional	NULL
relationship	NULL
exists	NULL
between	NULL
Stat3	NULL
and	NULL
IgH-enhancer	NULL
activation	NULL
,	NULL
we	NULL
reasoned	NULL
that	NULL
interference	NULL
with	NULL
endogenous	NULL
Stat3	NULL
function	NULL
should	NULL
disrupt	NULL
the	NULL
effect	NULL
of	NULL
gp130	NULL
on	NULL
the	NULL
IgH-enhancer	NULL
.	NULL

Stat3EE	NULL
is	NULL
a	NULL
Stat3	NULL
mutant	NULL
that	NULL
is	NULL
incapable	NULL
of	NULL
DNA	NULL
binding	NULL
,	NULL
yet	NULL
maintains	NULL
its	NULL
tyrosine	NULL
phosphorylation	NULL
site	NULL
.	NULL
``	NULL

''	NULL
Utilizing	NULL
this	NULL
mutant	NULL
as	NULL
a	NULL
potential	NULL
dominant	NULL
negative	NULL
construct	NULL
that	NULL
can	NULL
interfere	NULL
with	NULL
activation	NULL
of	NULL
the	NULL
IgH-enhancer	NULL
by	NULL
endogenous	NULL
Stat3	NULL
,	NULL
the	NULL
A2	NULL
cell	NULL
line	NULL
was	NULL
transiently	NULL
transfected	NULL
with	NULL
cDNA	NULL
copies	NULL
of	NULL
both	NULL
the	NULL
IgH	NULL
enhancer	NULL
and	NULL
Stat3EE	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
we	NULL
also	NULL
cotransfected	NULL
A2	NULL
cells	NULL
with	NULL
an	NULL
equal	NULL
amount	NULL
of	NULL
wild-type	NULL
Stat3	NULL
or	NULL
empty	NULL
vector	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IL-6	NULL
or	NULL
EGF	NULL
for	NULL
14	NULL
hr	NULL
and	NULL
then	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

In	NULL
A2	NULL
cells	NULL
cotransfected	NULL
with	NULL
the	NULL
empty	NULL
vector	NULL
,	NULL
treatment	NULL
with	NULL
IL-6	NULL
and	NULL
EGF	NULL
induced	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
2+3-	NULL
and	NULL
2-2-fold	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
)	NULL
.	NULL

In	NULL
A2	NULL
cells	NULL
transfected	NULL
with	NULL
wild-type	NULL
Stat3	NULL
,	NULL
EGF	NULL
stimulated	NULL
IgH-enhancer	NULL
activity	NULL
3:5-fold	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cotransfection	NULL
of	NULL
Stat3EE	NULL
abrogated	NULL
IgH-enhancer	NULL
responsiveness	NULL
to	NULL
both	NULL
IL-6	NULL
or	NULL
EGF	NULL
treatment	NULL
©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
350-357	NULL
Chimeric	NULL
gp130	NULL
induces	NULL
Ig	NULL
M	NULL
in	NULL
a	NULL
Stat3-dependent	NULL
fashion	NULL
355	NULL
6	NULL
©	NULL
Media	NULL
®	NULL
IL-6	NULL
4	NULL
®	NULL
EGF	NULL
(	NULL
48	NULL
)	NULL
5	NULL
3-5	NULL
3	NULL
8	NULL
3	NULL
8	NULL
5	NULL
4	NULL
o	NULL
E	NULL
(	NULL
32	NULL
)	NULL
(	NULL
31	NULL
)	NULL
25	NULL
[	NULL
<	NULL
?	NULL

3	NULL
3	NULL
2	NULL
5	NULL
22	NULL
F	NULL
G	NULL
§	NULL
2	NULL
t5	NULL
6	NULL
3	NULL
|	NULL
P	NULL
)	NULL
o	NULL
ko	NULL
_	NULL
o	NULL
I	NULL
1	NULL
05	NULL
0	NULL
AF10	NULL
SWK	NULL
A2	NULL
Stats	NULL
0	NULL
_	NULL
wt	NULL
Stat3	NULL
Stats	NULL
EE	NULL
0	NULL
_	NULL
wt	NULL
Stat3	NULL
Stats	NULL
EE	NULL
Transfection	NULL
|	NULL
]	NULL
L	NULL
|	NULL
AF10	NULL
A2	NULL
Figure	NULL
5	NULL
.	NULL

Stat3	NULL
is	NULL
involved	NULL
in	NULL
mediating	NULL
the	NULL
effect	NULL
of	NULL
gp130	NULL
on	NULL
an	NULL
IgH-enhancer	NULL
reporter	NULL
construct	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Induction	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
luciferase	NULL
activity	NULL
by	NULL
IL-6	NULL
and	NULL
EGF	NULL
.	NULL

Aliquots	NULL
of	NULL
3	NULL
x	NULL
10°	NULL
AFIO	NULL
,	NULL
SKW6.4	NULL
and	NULL
A2	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
8	NULL
ug	NULL
of	NULL
the	NULL
IgH-luciferase	NULL
construct	NULL
.	NULL

After	NULL
resting	NULL
for	NULL
14	NULL
hr	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
media	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
U/ml	NULL
IL-6	NULL
or	NULL
100	NULL
ng/ml	NULL
EGF	NULL
for	NULL
6	NULL
hr	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
lysed	NULL
,	NULL
equalized	NULL
for	NULL
protein	NULL
concentration	NULL
and	NULL
analysed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

The	NULL
efficiency	NULL
of	NULL
transfection	NULL
was	NULL
monitored	NULL
by	NULL
cotransfection	NULL
with	NULL
a	NULL
pSV	NULL
BGal	NULL
reporter	NULL
plasmid	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

The	NULL
panel	NULL
for	NULL
A2	NULL
cells	NULL
on	NULL
the	NULL
right-hand	NULL
side	NULL
represents	NULL
a	NULL
second	NULL
experiment	NULL
in	NULL
which	NULL
IL-6	NULL
and	NULL
EGF	NULL
were	NULL
combined	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Effect	NULL
of	NULL
Stat3EE	NULL
on	NULL
IgH	NULL
activity	NULL
;	NULL
aliquots	NULL
of	NULL
3	NULL
x	NULL
10°	NULL
AFIO	NULL
and	NULL
A2	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
8	NULL
ug	NULL
of	NULL
the	NULL
IgH-enhancer	NULL
reporter	NULL
construct	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
ug	NULL
control	NULL
vector	NULL
,	NULL
wild-type	NULL
Stat3	NULL
(	NULL
wt	NULL
Stat3	NULL
)	NULL
or	NULL
mutant	NULL
Stat3	NULL
(	NULL
Stat3EE	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
treated	NULL
as	NULL
above	NULL
.	NULL

These	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
experiments	NULL
.	NULL

in	NULL
A2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
Stat3EE	NULL
acts	NULL
as	NULL
a	NULL
dominant	NULL
negative	NULL
protein	NULL
in	NULL
this	NULL
system	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
the	NULL
endogenous	NULL
IL-6R	NULL
utilizes	NULL
Stat3	NULL
to	NULL
induce	NULL
the	NULL
IgH-enhancer	NULL
activity	NULL
,	NULL
we	NULL
also	NULL
looked	NULL
at	NULL
the	NULL
effect	NULL
of	NULL
dominant	NULL
negative	NULL
Stat3EE	NULL
in	NULL
AFIO	NULL
cells	NULL
AFIO	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
IgH	NULL
reporter	NULL
construct	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
control	NULL
vector	NULL
,	NULL
responded	NULL
to	NULL
IL-6	NULL
treatment	NULL
by	NULL
increased	NULL
IgH	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
wild-type	NULL
Stat3	NULL
generated	NULL
a	NULL
modest	NULL
increase	NULL
in	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
IgH	NULL
enhancer	NULL
,	NULL
reporter	NULL
activity	NULL
in	NULL
AFIO	NULL
cells	NULL
,	NULL
which	NULL
was	NULL
further	NULL
increased	NULL
upon	NULL
treatment	NULL
with	NULL
IL-6	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
)	NULL
.	NULL

Transfection	NULL
of	NULL
Stat3EE	NULL
in	NULL
AFIO	NULL
cells	NULL
blocked	NULL
IgH-enhancer	NULL
activation	NULL
by	NULL
IL-6	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
endogenous	NULL
IL-6R	NULL
also	NULL
induced	NULL
transcriptional	NULL
activity	NULL
via	NULL
Stat3	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
show	NULL
that	NULL
ligation	NULL
of	NULL
a	NULL
chimeric	NULL
gp130	NULL
protein	NULL
can	NULL
induce	NULL
IgM	NULL
production	NULL
in	NULL
SKW6.4	NULL
cells	NULL
along	NULL
with	NULL
Stat3	NULL
activation	NULL
.	NULL

Stat3	NULL
activation	NULL
was	NULL
initiated	NULL
at	NULL
the	NULL
level	NULL
of	NULL
the	NULL
receptor	NULL
,	NULL
where	NULL
consensus	NULL
tyrosine-based	NULL
motifs	NULL
were	NULL
required	NULL
in	NULL
order	NULL
for	NULL
gp130	NULL
to	NULL
induce	NULL
hSIE	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
complexes	NULL
and	NULL
enhanced	NULL
IgM	NULL
production	NULL
.	NULL

In	NULL
parallel	NULL
to	NULL
its	NULL
effect	NULL
on	NULL
IgM	NULL
production	NULL
,	NULL
engagement	NULL
of	NULL
chimeric	NULL
gp130	NULL
and	NULL
the	NULL
endogenous	NULL
IL-6R	NULL
induced	NULL
transcriptional	NULL
activation	NULL
of	NULL
a	NULL
transfected	NULL
IgH-enhancer	NULL
reporter	NULL
construct	NULL
.	NULL

Stat3EE	NULL
,	NULL
a	NULL
mutant	NULL
Stat3	NULL
incapable	NULL
of	NULL
binding	NULL
DNA	NULL
,	NULL
interfered	NULL
with	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
Ig	NULL
H-enhancer	NULL
reporter	NULL
.	NULL

SKW6.4	NULL
is	NULL
a	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
that	NULL
responds	NULL
to	NULL
IL-6	NULL
©	NULL
1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
350-357	NULL
with	NULL
increased	NULL
IgM	NULL
secretion	NULL
.	NULL
``	NULL

Because	NULL
the	NULL
endogenous	NULL
IL-6R	NULL
would	NULL
interfere	NULL
with	NULL
the	NULL
assessment	NULL
of	NULL
mutated	NULL
gp130	NULL
receptor	NULL
subunits	NULL
,	NULL
we	NULL
used	NULL
chimeric	NULL
gp130	NULL
receptors	NULL
to	NULL
look	NULL
at	NULL
the	NULL
effect	NULL
of	NULL
Stat	NULL
proteins	NULL
on	NULL
IgM	NULL
production	NULL
.	NULL

We	NULL
demonstrated	NULL
that	NULL
the	NULL
chimeric	NULL
gp130	NULL
receptors	NULL
could	NULL
induce	NULL
measurable	NULL
biochemical	NULL
signals	NULL
in	NULL
stable	NULL
transfected	NULL
SKW6.4	NULL
cells	NULL
.	NULL

Expression	NULL
of	NULL
full-length	NULL
chimeric	NULL
receptor	NULL
showed	NULL
EGF-inducible	NULL
phosphorylation	NULL
of	NULL
the	NULL
intracellular	NULL
tail	NULL
of	NULL
chimeric	NULL
receptors	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
is	NULL
likely	NULL
because	NULL
of	NULL
dimerization	NULL
of	NULL
gp130	NULL
subunits	NULL
which	NULL
bring	NULL
opposing	NULL
receptor-associated	NULL
JAK	NULL
to	NULL
proximity	NULL
with	NULL
one	NULL
another	NULL
followed	NULL
by	NULL
transphos-phorylation	NULL
and	NULL
Accordingly	NULL
,	NULL
we	NULL
found	NULL
constitutive	NULL
as	NULL
well	NULL
as	NULL
inducible	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
JAK1	NULL
in	NULL
A2	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Activated	NULL
JAK	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
play	NULL
a	NULL
role	NULL
in	NULL
initiating	NULL
downstream	NULL
signalling	NULL
events	NULL
at	NULL
the	NULL
level	NULL
of	NULL
gp130	NULL
by	NULL
phosphorylating	NULL
consensus	NULL
tyrosine	NULL
phosphorylation	NULL
sites	NULL
.	NULL

``	NULL
``	NULL
~	NULL
``	NULL
>	NULL
>	NULL
Because	NULL
the	NULL
D4	NULL
receptor	NULL
contains	NULL
no	NULL
Stat3	NULL
consensus	NULL
sites	NULL
,	NULL
we	NULL
could	NULL
not	NULL
discern	NULL
any	NULL
phosphorylation	NULL
upon	NULL
EGF	NULL
treatment	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Differences	NULL
in	NULL
receptor	NULL
tyrosine	NULL
phosphorylation	NULL
were	NULL
reflected	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
subsequent	NULL
signalling	NULL
pathways	NULL
.	NULL

Tyrosine	NULL
phosphorylation	NULL
of	NULL
gp130	NULL
at	NULL
consensus	NULL
YXXQ	NULL
motifs	NULL
provides	NULL
binding	NULL
sites	NULL
for	NULL
Stat3	NULL
proteins	NULL
.	NULL
``	NULL

After	NULL
recruitment	NULL
to	NULL
these	NULL
sites	NULL
,	NULL
Stat3	NULL
proteins	NULL
are	NULL
phosphorylated	NULL
on	NULL
tyrosine	NULL
residues	NULL
by	NULL
receptor-associated	NULL
JAK	NULL
kinases	NULL
.	NULL

``	NULL
``	NULL
>	NULL
>	NULL
``	NULL
In	NULL
accordance	NULL
with	NULL
these	NULL
facts	NULL
,	NULL
EGF	NULL
induced	NULL
Stat3	NULL
phosphorylation	NULL
in	NULL
A2	NULL
cells	NULL
,	NULL
but	NULL
failed	NULL
to	NULL
induce	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Stat3	NULL
in	NULL
D4	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Since	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Stat3	NULL
affects	NULL
dimerization	NULL
and	NULL
binding	NULL
to	NULL
GAS-like	NULL
DNA	NULL
356	NULL
elements	NULL
,	NULL
``	NULL
``	NULL
``	NULL
*	NULL
>	NULL
``	NULL
it	NULL
was	NULL
not	NULL
surprising	NULL
that	NULL
EGF	NULL
induced	NULL
hSIE	NULL
binding	NULL
complexes	NULL
in	NULL
A2	NULL
but	NULL
not	NULL
D4	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
recruiting	NULL
signalling	NULL
components	NULL
to	NULL
the	NULL
receptor	NULL
,	NULL
the	NULL
tyrosine-based	NULL
modular	NULL
domains	NULL
in	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
gp130	NULL
regulate	NULL
the	NULL
biological	NULL
effect	NULL
of	NULL
the	NULL
IL-6R	NULL
.	NULL

Engagement	NULL
of	NULL
the	NULL
chimeric	NULL
receptor	NULL
carrying	NULL
all	NULL
four	NULL
Stat3-binding	NULL
motifs	NULL
induced	NULL
the	NULL
production	NULL
of	NULL
IgM	NULL
in	NULL
stable	NULL
transfected	NULL
A2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
chimeric	NULL
receptors	NULL
that	NULL
lack	NULL
the	NULL
tyrosine-based	NULL
motifs	NULL
failed	NULL
to	NULL
induce	NULL
IgM	NULL
secretion	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

To	NULL
explore	NULL
more	NULL
directly	NULL
the	NULL
relationship	NULL
between	NULL
IgM	NULL
secretion	NULL
and	NULL
Stat3	NULL
activation	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
gp130	NULL
on	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer	NULL
.	NULL

The	NULL
IgH	NULL
enhancer	NULL
is	NULL
an	NULL
intronic	NULL
sequence	NULL
located	NULL
5	NULL
'	NULL
of	NULL
the	NULL
Ig	NULL
u	NULL
locus'*	NULL
``	NULL
``	NULL
and	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
up-regulating	NULL
the	NULL
rate	NULL
of	NULL
transcription	NULL
of	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
genes	NULL
.	NULL
``	NULL

''	NULL
``	NULL
``	NULL
Although	NULL
multiple	NULL
positive	NULL
and	NULL
negative	NULL
binding	NULL
sites	NULL
have	NULL
been	NULL
characterized	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
,	NULL
``	NULL
°**	NULL
'	NULL
it	NULL
has	NULL
not	NULL
been	NULL
shown	NULL
that	NULL
Stat	NULL
proteins	NULL
can	NULL
affect	NULL
this	NULL
element	NULL
.	NULL

Ligation	NULL
of	NULL
the	NULL
chimeric	NULL
gp130	NULL
receptor	NULL
in	NULL
A2	NULL
cells	NULL
increased	NULL
the	NULL
activity	NULL
of	NULL
an	NULL
IgH-enhancer	NULL
reporter	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

5a	NULL
)	NULL
.	NULL

This	NULL
effect	NULL
occurred	NULL
in	NULL
parallel	NULL
with	NULL
Stat3	NULL
activation	NULL
and	NULL
IgM	NULL
secretion	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
and	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
IgH-enhancer	NULL
activity	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
cells	NULL
that	NULL
failed	NULL
to	NULL
activate	NULL
Stat3	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
chimeric	NULL
receptor	NULL
on	NULL
IgH-enhancer	NULL
reporter	NULL
is	NULL
mediated	NULL
by	NULL
Stat3	NULL
pro-teins	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
function	NULL
of	NULL
activated	NULL
Stat3	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
we	NULL
made	NULL
use	NULL
of	NULL
a	NULL
mutant	NULL
Stat3	NULL
construct	NULL
,	NULL
Stat3EE	NULL
,	NULL
which	NULL
contains	NULL
substitutions	NULL
of	NULL
two	NULL
critical	NULL
amino	NULL
acids	NULL
in	NULL
its	NULL
DNA	NULL
binding	NULL
domain	NULL
,	NULL
and	NULL
fails	NULL
to	NULL
bind	NULL
DNA	NULL
response	NULL
elements	NULL
.	NULL
``	NULL

Because	NULL
the	NULL
Stat3EE	NULL
protein	NULL
still	NULL
undergoes	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
``	NULL
we	NULL
reasoned	NULL
that	NULL
the	NULL
Stat3EE	NULL
protein	NULL
may	NULL
function	NULL
as	NULL
a	NULL
dominant	NULL
negative	NULL
protein	NULL
which	NULL
competes	NULL
with	NULL
endogenous	NULL
Stat3	NULL
.	NULL

Indeed	NULL
,	NULL
cotransfection	NULL
of	NULL
Stat3EE	NULL
prevented	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IgH-enhancer	NULL
reporter	NULL
by	NULL
the	NULL
chimeric	NULL
receptors	NULL
in	NULL
A2	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5b	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
wild-type	NULL
Stat3	NULL
cotransfection	NULL
enhanced	NULL
the	NULL
response	NULL
.	NULL

In	NULL
order	NULL
to	NULL
show	NULL
that	NULL
this	NULL
effect	NULL
is	NULL
not	NULL
an	NULL
artifact	NULL
induced	NULL
by	NULL
the	NULL
chimeric	NULL
receptor	NULL
,	NULL
we	NULL
also	NULL
showed	NULL
that	NULL
StatEE	NULL
abrogated	NULL
the	NULL
stimulating	NULL
effect	NULL
of	NULL
the	NULL
endogenous	NULL
IL-6R	NULL
on	NULL
the	NULL
IgH-enhancer	NULL
reporter	NULL
in	NULL
AFIO	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
preliminary	NULL
data	NULL
in	NULL
our	NULL
laboratory	NULL
showing	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
mobility	NULL
shift	NULL
complex	NULL
with	NULL
a	NULL
non-consensus	NULL
Stat-like	NULL
binding	NULL
site	NULL
corresponding	NULL
to	NULL
nucleotides	NULL
88	NULL
to	NULL
96	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
(	NULL
TTAGAGCAA	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Since	NULL
it	NULL
is	NULL
not	NULL
possible	NULL
at	NULL
this	NULL
stage	NULL
to	NULL
demonstrate	NULL
by	NULL
transient	NULL
transfection	NULL
the	NULL
effect	NULL
of	NULL
Stat3EE	NULL
on	NULL
endogenous	NULL
immunoglobulin	NULL
genes	NULL
,	NULL
we	NULL
aim	NULL
to	NULL
explore	NULL
in	NULL
future	NULL
experiments	NULL
the	NULL
effect	NULL
of	NULL
stable	NULL
,	NULL
inducible	NULL
Stat3EE	NULL
expression	NULL
on	NULL
IgM	NULL
induction	NULL
.	NULL

These	NULL
data	NULL
do	NULL
not	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
IL-6	NULL
exerts	NULL
its	NULL
effect	NULL
by	NULL
acting	NULL
on	NULL
additional	NULL
cellular	NULL
targets	NULL
,	NULL
such	NULL
as	NULL
enhancing	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
J	NULL
chain	NULL
.	NULL
``	NULL

''	NULL
Taken	NULL
together	NULL
,	NULL
the	NULL
above	NULL
findings	NULL
demonstrate	NULL
that	NULL
IL-6	NULL
,	NULL
by	NULL
way	NULL
of	NULL
Stat3	NULL
,	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
humoral	NULL
arm	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
and	NULL
affects	NULL
an	NULL
important	NULL
aspect	NULL
of	NULL
B-cell	NULL
differentiation	NULL
.	NULL

This	NULL
complements	NULL
recent	NULL
studies	NULL
that	NULL
have	NULL
shown	NULL
the	NULL
importance	NULL
of	NULL
Statl	NULL
in	NULL
innate	NULL
immunity	NULL
against	NULL
viral	NULL
infections	NULL
.	NULL
``	NULL

''	NULL
ACKNOWLEDGMENT	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
United	NULL
States	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
,	NULL
CA-09120-21	NULL
and	NULL
AI-34567	NULL
(	NULL
UCLA	NULL
Asthma	NULL
,	NULL
Allergy	NULL
and	NULL
Immunology	NULL
Center	NULL
funded	NULL
by	NULL
the	NULL
NIAID	NULL
and	NULL
NIEHS	NULL
)	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

M.	NULL
Faris	NULL
et	NULL
al	NULL
.	NULL

REFERENCES	NULL
.	NULL

Van	NULL
Snick	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Interleukin-6	NULL
:	NULL
an	NULL
overview	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
8	NULL
,	NULL
253.	NULL
.	NULL

Hirano	NULL
T.	NULL
,	NULL
Akira	NULL
S.	NULL
,	NULL
Taga	NULL
T.	NULL
&	NULL
KisHimoto	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
Biological	NULL
and	NULL
clinical	NULL
aspects	NULL
of	NULL
interleukin-6	NULL
.	NULL

Immunol	NULL
Today	NULL
11	NULL
,	NULL
443.	NULL
.	NULL

SeHGaL	NULL
P.B	NULL
.	NULL

,	NULL
WaNnG	NULL
L.	NULL
,	NULL
Rayanape	NULL
R.	NULL
,	NULL
Pan	NULL
H.	NULL
&	NULL
MarouLues	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
Interleukin-6-type	NULL
cytokines	NULL
.	NULL

Ann	NULL
NY	NULL
Acad	NULL
Sci	NULL
762	NULL
,	NULL
1.	NULL
.	NULL

BeRToLNI	NULL
J.N	NULL
.	NULL

&	NULL
Benson	NULL
EM	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
The	NULL
role	NULL
of	NULL
human	NULL
interleukin-6	NULL
in	NULL
B	NULL
cell	NULL
isotype	NULL
regulation	NULL
and	NULL
differentiation	NULL
.	NULL

Cel/	NULL
Immunol	NULL
125	NULL
,	NULL
197.	NULL
.	NULL

MuragucHt	NULL
A.	NULL
,	NULL
Hirano	NULL
T.	NULL
,	NULL
TANG	NULL
B.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
The	NULL
essential	NULL
role	NULL
of	NULL
B	NULL
cell	NULL
stimulatory	NULL
factor	NULL
2	NULL
(	NULL
BSF-2/IL-6	NULL
)	NULL
for	NULL
the	NULL
terminal	NULL
differentiatin	NULL
of	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
167	NULL
,	NULL
332.	NULL
.	NULL

Kumar	NULL
G.	NULL
,	NULL
GUPTA	NULL
S.	NULL
,	NULL
Wancg	NULL
S.	NULL
&	NULL
NEL	NULL
A.E	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
.	NULL

Involvemet	NULL
of	NULL
Janus	NULL
kinases	NULL
,	NULL
p52	NULL
``	NULL
,	NULL
Raf-1	NULL
,	NULL
and	NULL
MEK-1	NULL
in	NULL
the	NULL
IL-6	NULL
induced	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
cascade	NULL
of	NULL
a	NULL
growth-responsive	NULL
B	NULL
cell	NULL
line	NULL
.	NULL

J	NULL
Immunol	NULL
153	NULL
,	NULL
4436.	NULL
.	NULL

SipeLt	NULL
N.	NULL
,	NULL
Taga	NULL
T.	NULL
,	NULL
Hirano	NULL
T.	NULL
,	NULL
T.	NULL
&	NULL
Saxon	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Retinoic	NULL
acid-induced	NULL
growth	NULL
inhibition	NULL
of	NULL
a	NULL
human	NULL
myeloma	NULL
cell	NULL
line	NULL
via	NULL
down-regulation	NULL
of	NULL
the	NULL
IL-6	NULL
receptors	NULL
.	NULL

J	NULL
Immuno	NULL
!	NULL

146	NULL
,	NULL
3809.	NULL
.	NULL

GoLpstEIN	NULL
H.	NULL
,	NULL
KosrnoLz	NULL
D.	NULL
,	NULL
CHESKY	NULL
L.	NULL
,	NULL
Fan	NULL
X	NULL
.	NULL

&	NULL
Amesrus	NULL
J.L	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Divergent	NULL
activities	NULL
of	NULL
protein	NULL
kinases	NULL
in	NULL
IL-6-induced	NULL
differentiation	NULL
of	NULL
a	NULL
human	NULL
B	NULL
cell	NULL
line	NULL
.	NULL

J	NULL
Immunol	NULL
145	NULL
,	NULL
952.	NULL
.	NULL

DARNELL	NULL
J.E	NULL
.	NULL

,	NULL
Kerr	NULL
LM	NULL
.	NULL

&	NULL
Stark	NULL
G.R	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Jak-STAT	NULL
pathways	NULL
and	NULL
transcriptional	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
IFNs	NULL
and	NULL
other	NULL
extracellular	NULL
signaling	NULL
proteins	NULL
.	NULL

Science	NULL
264	NULL
,	NULL
1415	NULL
.	NULL

IxLe	NULL
J.N	NULL
.	NULL

&	NULL
Kerr	NULL
LM	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Jaks	NULL
and	NULL
Stats	NULL
in	NULL
signaling	NULL
by	NULL
cytokine	NULL
receptor	NULL
superfamily	NULL
.	NULL

Trends	NULL
Genet	NULL
11	NULL
,	NULL
69	NULL
.	NULL

STAHL	NULL
N.	NULL
,	NULL
FarRUGGELLA	NULL
T.J.	NULL
,	NULL
Bourton	NULL
T.G	NULL
.	NULL

,	NULL
Zong	NULL
Z.	NULL
,	NULL
DarNELL	NULL
J.E	NULL
.	NULL

&	NULL
Yancoroutos	NULL
G.D.	NULL
(	NULL
1995	NULL
)	NULL
Choice	NULL
of	NULL
STATs	NULL
and	NULL
other	NULL
substrates	NULL
specified	NULL
by	NULL
modular	NULL
tyrosine-based	NULL
motifs	NULL
in	NULL
cytokine	NULL
receptors	NULL
.	NULL

Science	NULL
267	NULL
,	NULL
1349	NULL
.	NULL

MURAKAMI	NULL
M.	NULL
,	NULL
NaARAZAKI	NULL
M.	NULL
,	NULL
Hist	NULL
M.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Critical	NULL
cytoplasmic	NULL
region	NULL
of	NULL
the	NULL
interleukin	NULL
6	NULL
signal	NULL
transducer	NULL
gp130	NULL
is	NULL
conserved	NULL
in	NULL
the	NULL
cytokine	NULL
receptor	NULL
family	NULL
.	NULL

Proc	NULL
Nat	NULL
!	NULL

Acad	NULL
Sci	NULL
USA	NULL
88	NULL
,	NULL
11	NULL
349.	NULL
.	NULL

MUraMAKI	NULL
M.	NULL
,	NULL
Hist	NULL
M.	NULL
,	NULL
NAKAGAWA	NULL
N.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
IL-6-induced	NULL
homodimerization	NULL
of	NULL
gp130	NULL
and	NULL
associated	NULL
activation	NULL
of	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Science	NULL
260	NULL
,	NULL
1808.	NULL
.	NULL

Stan	NULL
N.	NULL
,	NULL
BouLton	NULL
TG	NULL
.	NULL

,	NULL
FarRUGGELLA	NULL
T.	NULL
et	NULL
al	NULL
(	NULL
1994	NULL
)	NULL
Association	NULL
and	NULL
activation	NULL
of	NULL
Jak-Tyk	NULL
kinases	NULL
by	NULL
CNTF-LIF-OSM-IL-6	NULL
$	NULL
receptor	NULL
component	NULL
.	NULL

Science	NULL
263	NULL
,	NULL
92	NULL
.	NULL

LUTTICKEN	NULL
L.	NULL
,	NULL
WeaEnka	NULL
U.M	NULL
.	NULL

,	NULL
YuaN	NULL
J.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Association	NULL
of	NULL
transcription	NULL
factor	NULL
APRF	NULL
and	NULL
protein	NULL
kinase	NULL
Jak1	NULL
with	NULL
the	NULL
interleukin-6	NULL
signal	NULL
transducer	NULL
gp130	NULL
.	NULL

Science	NULL
263	NULL
,	NULL
89	NULL
.	NULL

Rassitts	NULL
TH	NULL
.	NULL

,	NULL
ForsTER	NULL
A.	NULL
,	NULL
Barr	NULL
R.	NULL
&	NULL
HamIyN	NULL
PH	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Transcription	NULL
enhancer	NULL
identified	NULL
near	NULL
the	NULL
human	NULL
ca	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
gene	NULL
is	NULL
unavailable	NULL
to	NULL
the	NULL
translocated	NULL
c-myc	NULL
gene	NULL
in	NULL
a	NULL
Burkitt	NULL
lymphoma	NULL
.	NULL

Nature	NULL
306	NULL
,	NULL
806.	NULL
.	NULL

Horvath	NULL
C.M	NULL
.	NULL

,	NULL
Wen	NULL
Z	NULL
.	NULL

&	NULL
DarneLt	NULL
J.E	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
A	NULL
STAT	NULL
protein	NULL
domain	NULL
that	NULL
determines	NULL
DNA	NULL
sequence	NULL
recognition	NULL
suggests	NULL
a	NULL
novel	NULL
DNA-binding	NULL
domain	NULL
.	NULL

Genes	NULL
Devel	NULL
9	NULL
,	NULL
984.	NULL
.	NULL

FaARIS	NULL
M.	NULL
,	NULL
Ensout	NULL
B.	NULL
,	NULL
STAHL	NULL
N.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Differential	NULL
activation	NULL
of	NULL
the	NULL
ERK	NULL
,	NULL
JNK	NULL
and	NULL
JAK-Stat	NULL
pathways	NULL
by	NULL
oncostatin	NULL
M	NULL
and	NULL
basic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
in	NULL
AIDS-derived	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
cells	NULL
.	NULL

AIDS	NULL
10	NULL
,	NULL
369	NULL
.	NULL

Macy	NULL
E.	NULL
,	NULL
Kemeny	NULL
M.	NULL
&	NULL
Saxon	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Enhanced	NULL
ELISA	NULL
:	NULL
how	NULL
to	NULL
measure	NULL
less	NULL
than	NULL
10	NULL
picograms	NULL
of	NULL
a	NULL
specific	NULL
protein	NULL
(	NULL
Immunoglobulin	NULL
)	NULL
in	NULL
less	NULL
than	NULL
8	NULL
hours	NULL
.	NULL

FASEB	NULL
J	NULL
2	NULL
,	NULL
3003	NULL
.	NULL

NarAZzAKI	NULL
M.	NULL
,	NULL
WirtHurmn	NULL
B.A	NULL
.	NULL

,	NULL
YosHipa	NULL
K.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Activation	NULL
of	NULL
JAK2	NULL
kinase	NULL
mediated	NULL
by	NULL
the	NULL
interleukin-6	NULL
signal	NULL
transducer	NULL
gp130	NULL
.	NULL

Proc	NULL
Nat	NULL
!	NULL

Acad	NULL
Sci	NULL
USA	NULL
91	NULL
,	NULL
2285	NULL
.	NULL

GuscHin	NULL
D.	NULL
,	NULL
Rogers	NULL
N.	NULL
,	NULL
Briscor	NULL
J.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
A	NULL
major	NULL
role	NULL
for	NULL
the	NULL
protein	NULL
kinase	NULL
JAK	NULL
1	NULL
in	NULL
the	NULL
JAK/STAT	NULL
signal	NULL
transduction	NULL
pathway	NULL
in	NULL
response	NULL
to	NULL
IL-6	NULL
.	NULL

EMBO	NULL
J	NULL
14	NULL
,	NULL
1421	NULL
.	NULL

©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
350-357	NULL
22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

Chimeric	NULL
gp130	NULL
induces	NULL
Ig	NULL
M	NULL
in	NULL
a	NULL
Stat3-dependent	NULL
fashion	NULL
WeoEnkaA	NULL
U.M	NULL
.	NULL

,	NULL
LUTTICKEN	NULL
C.	NULL
,	NULL
BUSCHMAN	NULL
J.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
The	NULL
interleukin-6-activated	NULL
acute	NULL
phase	NULL
response	NULL
factor	NULL
is	NULL
antigenically	NULL
and	NULL
functionally	NULL
related	NULL
to	NULL
members	NULL
of	NULL
the	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
(	NULL
STAT	NULL
)	NULL
family	NULL
.	NULL

Mol	NULL
Cell	NULL
Bio	NULL
!	NULL

14	NULL
,	NULL
3186	NULL
.	NULL

Wecenka	NULL
U.M	NULL
.	NULL

,	NULL
BuscHman	NULL
J.	NULL
,	NULL
Lutticken	NULL
C.	NULL
,	NULL
HemricH	NULL
P.C	NULL
.	NULL

&	NULL
Horn	NULL
F.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Acute-phase	NULL
response	NULL
factor	NULL
,	NULL
a	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
acute	NULL
phase	NULL
response	NULL
elements	NULL
,	NULL
is	NULL
rapidly	NULL
activated	NULL
by	NULL
interleukin-6	NULL
at	NULL
the	NULL
posttranslational	NULL
level	NULL
.	NULL

Molec	NULL
Cell	NULL
Biol	NULL
13	NULL
,	NULL
276	NULL
.	NULL

AKIRA	NULL
S.	NULL
,	NULL
Nismo	NULL
Y.	NULL
,	NULL
Inove	NULL
M.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Molecular	NULL
cloning	NULL
of	NULL
APRF	NULL
,	NULL
a	NULL
novel	NULL
IFN-stimulated	NULL
gene	NULL
factor	NULL
3	NULL
p91-related	NULL
transcription	NULL
factor	NULL
involved	NULL
in	NULL
the	NULL
gp130-mediated	NULL
signaling	NULL
pathway	NULL
.	NULL

Cell	NULL
77	NULL
,	NULL
63	NULL
.	NULL

ScHaAEFER	NULL
T.S	NULL
.	NULL

,	NULL
SANDERS	NULL
LK	NULL
.	NULL

&	NULL
NatHANs	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
Cooperative	NULL
transcriptional	NULL
activity	NULL
of	NULL
Jun	NULL
and	NULL
Stat3	NULL
$	NULL
,	NULL
a	NULL
short	NULL
form	NULL
of	NULL
Stat3	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
92	NULL
,	NULL
9097	NULL
.	NULL

Raynat	NULL
M-C.	NULL
,	NULL
Liv	NULL
Z.	NULL
,	NULL
Hirano	NULL
T.	NULL
,	NULL
Mayer	NULL
L.	NULL
,	NULL
KisHimoto	NULL
T.	NULL
&	NULL
CHEnN-Kianc	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
Interleukin	NULL
6	NULL
induces	NULL
secretion	NULL
of	NULL
IgG1	NULL
by	NULL
coordinated	NULL
transcriptional	NULL
activation	NULL
and	NULL
differential	NULL
mRNA	NULL
accumulation	NULL
.	NULL

Proc	NULL
Nat	NULL
!	NULL

Acad	NULL
Sci	NULL
USA	NULL
86	NULL
,	NULL
8024	NULL
.	NULL

BaneRi1	NULL
J.	NULL
,	NULL
Orson	NULL
L.	NULL
&	NULL
ScHarrner	NULL
W.	NULL
(	NULL
1983	NULL
)	NULL
A	NULL
lymphocyte-specific	NULL
cellular	NULL
enhancer	NULL
is	NULL
located	NULL
downstream	NULL
of	NULL
the	NULL
joining	NULL
region	NULL
in	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
genes	NULL
.	NULL

Cell	NULL
33	NULL
,	NULL
729	NULL
.	NULL

©1997	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Immunology	NULL
,	NULL
90	NULL
,	NULL
350-357	NULL
28	NULL
29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

357	NULL
ALT	NULL
F.W	NULL
.	NULL

,	NULL
OLTz	NULL
EM	NULL
.	NULL

,	NULL
Young	NULL
F.	NULL
,	NULL
GoRrMaN	NULL
J.	NULL
,	NULL
Tacciou	NULL
G.	NULL
&	NULL
CHEN	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
VDJ	NULL
recombination	NULL
.	NULL

Immunol	NULL
Today	NULL
13	NULL
,	NULL
306	NULL
.	NULL

Lenarpo	NULL
M.	NULL
,	NULL
Prerce	NULL
J.W	NULL
.	NULL

&	NULL
BaLTimore	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Protein-binding	NULL
sites	NULL
in	NULL
Ig	NULL
gene	NULL
enhancers	NULL
determine	NULL
transcriptional	NULL
activity	NULL
and	NULL
inducibility	NULL
.	NULL

Science	NULL
236	NULL
,	NULL
1573	NULL
.	NULL

Sen	NULL
R.	NULL
&	NULL
Baltimore	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Multiple	NULL
nuclear	NULL
factors	NULL
interact	NULL
with	NULL
the	NULL
immunoglobulin	NULL
enhancer	NULL
sequence	NULL
.	NULL

Cell	NULL
46	NULL
,	NULL
705	NULL
.	NULL

EpHrusst	NULL
A.	NULL
,	NULL
Cuuren	NULL
G.M	NULL
.	NULL

,	NULL
TonEcawa	NULL
S.	NULL
&	NULL
GictBERT	NULL
W.	NULL
(	NULL
1985	NULL
)	NULL
B	NULL
lineage-specific	NULL
interactions	NULL
of	NULL
an	NULL
immunoglobulin	NULL
enhancer	NULL
with	NULL
cellular	NULL
factors	NULL
in	NULL
vivo	NULL
.	NULL

Science	NULL
227	NULL
,	NULL
134	NULL
.	NULL

Ine	NULL
JN	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Cytokine	NULL
receptor	NULL
signaling	NULL
.	NULL

Nature	NULL
377	NULL
,	NULL
591	NULL
.	NULL

GrREENLUND	NULL
A.C.	NULL
,	NULL
Morares	NULL
M.O	NULL
.	NULL

,	NULL
Viviano	NULL
BL	NULL
.	NULL

,	NULL
Yan	NULL
H.	NULL
,	NULL
KroLtEwsk1	NULL
J	NULL
.	NULL

&	NULL
ScHurEiBER	NULL
RD	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Stat	NULL
recruitment	NULL
by	NULL
tyrosine-phosphorylated	NULL
cytokine	NULL
receptors	NULL
:	NULL
an	NULL
ordered	NULL
reversible	NULL
affinity-driven	NULL
process	NULL
.	NULL

Immunity	NULL
2	NULL
,	NULL
677	NULL
.	NULL

RANDALL	NULL
TD	NULL
.	NULL

,	NULL
Lunp	NULL
FE	NULL
.	NULL

,	NULL
Brewer	NULL
J.W	NULL
.	NULL

,	NULL
ALDRIDGE	NULL
C.	NULL
,	NULL
WALL	NULL
R.	NULL
&	NULL
CorLEY	NULL
R.B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Interleukin-5	NULL
(	NULL
IL-5	NULL
)	NULL
and	NULL
IL-6	NULL
define	NULL
two	NULL
molecularly	NULL
distinct	NULL
pathways	NULL
of	NULL
B-cell	NULL
differentiation	NULL
.	NULL

Mo	NULL
!	NULL

Cell	NULL
Biol	NULL
13	NULL
,	NULL
3929	NULL
.	NULL

Dursin	NULL
J.E	NULL
.	NULL

,	NULL
HackENMILLER	NULL
R.	NULL
,	NULL
Simon	NULL
M.C	NULL
.	NULL

&	NULL
Levy	NULL
D.E	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Targeted	NULL
disruption	NULL
of	NULL
the	NULL
mouse	NULL
Statl	NULL
gene	NULL
results	NULL
in	NULL
compromised	NULL
innate	NULL
immunity	NULL
to	NULL
viral	NULL
disease	NULL
.	NULL

Cell	NULL
84	NULL
,	NULL
443	NULL
.	NULL

